To see the other types of publications on this topic, follow the link: Gruppo IV.
Journal articles on the topic 'Gruppo IV'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Gruppo IV.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Piva, Paolo. "Metz: un gruppo episcopale alla svolta dei tempi (secoli IV-IX)." Antiquité Tardive 8 (January 2001): 237–64. http://dx.doi.org/10.1484/j.at.2.300701.
Full text
2
Martelli, A., M. Zanlungo, L. Sibilla, C. Uggetti, P. Merlo, F. Zappoli, and C. Consoli. "Studio TC del nervo ulnare nel canale di Guyon." Rivista di Neuroradiologia 7, no. 1 (February 1994): 109–13. http://dx.doi.org/10.1177/197140099400700115.
Full textAbstract:
Sono stati esaminati, mediante TC del polso e secondo una metodica standardizzata dagli autori, 50 soggetti con sindrome irritativa e/o deficitaria nel territorio del nervo ulnare al polso. In base ai rilievi TC sono stati differenziati 4 gruppi patologici: I) formazioni cistiche intra o extracanalari, II) calcificazioni dell'arteria ulnare, III) deformazione del piccolo canale, IV) mancata distinzione alla TC tra nervo e arteria. Nell'ambito dei diversi gruppi sono state identificate cause dirette ed indirette di compressione. Quindici pazienti sono stati sottoposti ad intervento chirurgico. Questo nei casi appartenenti al IV gruppo patologico ha dimostrato una fibrosi del paranervio con tralci fibrosi a ponte tra nervo ed arteria. Gli autori concludono che la TC rappresenta una metodica completa e a costo contenuto per lo studio delle sindromi canalari al polso.
3
Monini, S., C. M. Iacolucci, M. Di Traglia, A. I. Lazzarino, and M. Barbara. "Ruolo della riabilitazione Kabat nella paralisi del nervo facciale: studio randomizzato su casi severi di paralisi di Bell." Acta Otorhinolaryngologica Italica 36, no. 4 (August 2016): 282–88. http://dx.doi.org/10.14639/0392-100x-783.
Full textAbstract:
La terapia della paralisi di Bell, incentrata su farmaci steroidei e/o antivirali, può ancora far esitare nei soggetti affetti sequele disfiguranti per un recupero incompleto. Le diverse procedure riabilitative non si sono dimostrate al giorno d'oggi in grado di giocare un ruolo favorevole in questo senso. Scopo di questo lavoro è stato quello di mettere a confronto i risultati funzionali di pazienti affetti da forme severe di paralisi di Bell, quando trattati con solo cortisone con quelli nei quali al cortisone è stata affiancata una terapia riabilitativa secondo Kabat. Lo studio prospettico ha incluso 94 soggetti con paralisi di Bell di grado IV e V secondo House-Brackmann (HB) a loro volta suddivisi in due gruppi: (a) trattato con terapia steroidea; (b) trattato con terapia steroidea e riabilitazione Kabat. Il trattamento medico è consistito di 60 mg di prednisolone al giorno per 15 giorni; la terapia riabilitativa è consistita nel trattamento di facilitazione neuromuscolare propiocettiva secondo Kabat. Percentuale, grado e tempi di recupero sono stati comparati utilizzando l'analisi statistica Mann-Whitney e il test di regressione logistica multivariata (Ward test). I pazienti Kabat (gruppo b) hanno avuto 20 volte di più la possibilità di migliorare di 3 o più gradi HB (OR = 17,73, 95% IC = 5,72 a 54,98, p < 0,001) rispetto a quelli di gruppo a. La velocità media di recupero nel gruppo b è risultata la metà di quella registrata nel gruppo a. Nessuna differenza è stata invece riscontrata sull'incidenza di sincinesie. Si può dunque concludere che la terapia steroidea permette un migliore e più rapido recupero dei casi severi di paralisi di Bell, quando associata a terapia riabilitativa Kabat.
4
Manfrè, L., R. Angileri, G. Caruso, V. D'Antonio, M. De Maria, and R. Lagalla. "Calibro dei sifoni carotidei e asimmetria del poligono di Willis: Studio Angio-RM." Rivista di Neuroradiologia 10, no. 2_suppl (October 1997): 148. http://dx.doi.org/10.1177/19714009970100s260.
Full textAbstract:
A differenza dell'Angiografia, l'esame Angio-RM consente la simultanea visualizzazione dei vasi del poligono. Si è valutata la correlazione esistente tra calibro dei sifoni e asimmetrie di sviluppo del poligono nella popolazione normale. Sono stati esaminati 3 casi di occlusione totale di una carotide. 120 pazienti privi di patologie vascolari o neoplastiche sono stati sottoposti ad esame Angio-RM 3DTOF con Magnetization Tranfer e TONE. Sono state valutate le immagini di sorgente e 3DMIP, prima e dopo sottrazione dei pixel non vascolari. I pazienti sono stati suddivisi in 5 gruppi: I = aplasia di A1, II = ipoplasia di A1, III = lieve asimmetria di A1, IV ? arteria comunicante posteriore fetale, V = poligono simmetrico. Inoltre i pazienti sono stati suddivisi in base al calibro della carotide interna in: A (simmetrico), B (lieve asimmetria), e C (marcata asimmetria). è stata calcolata la percentuale di differenza di calibro (PDC) tra carotide destra e sinistra (Cmin/Cmax). Sono stati posti in correlazione PDC e simmetria dei vasi del poligono. I pazienti del gruppo C sono stati sottoposti a color Doppler dei vasi al collo, per escludere vasculopatia a monte. Una differenza statisticamente significativa in termini di PDC tra sifone carotideo destro e sinistro è stata osservata unicamente nei pazienti di gruppo I e II. I pazienti affetti da occlusione del sifone carotideo con compenso via Al dimostravano un calibro di Al superiore rispetto ai gruppi III, IV e V. Per quanto una asimmetria di calibro dei sifoni carotidei possa suggerire l'esistenza di una patologia vascolare a monte, è necessario considerare le varianti anatomiche correlate all'asimmetrico del poligono di Willis. Il bilancio dei rami collaterali esistenti a livello del poligono di Willis mediante Angio-RM è importante per la valutazione dei possibili circoli di compenso.
5
Vacante, Salvatore. "Le paludi di Eritre: un'interpretazione ecologico-ambientale." Klio 99, no. 2 (February 7, 2018): 399–419. http://dx.doi.org/10.1515/klio-2017-0032.
Full textAbstract:
Riassunto: Le fonti relative alle paludi di Eritre in Asia Minore sono qui riesaminate in chiave storico-ambientale. La menzione dell'organizzazione degli heleoreontes o ‚Guardiani delle paludi‘ su una pietra confinaria dai dintorni di Eritre fornisce evidenza circa l'amministrazione della chōra cittadina nel periodo tardo Classico – primo Ellenistico. Una nuova datazione per l'iscrizione è suggerita, precisamente al tardo IV secolo a. C., quando le città greche della costa anatolica furono conquistate dai Macedoni. I ‚Guardiani delle paludi‘ erano probabilmente membri di una delle chiliastyes (‚gruppi di mille‘) territoriali forse introdotte sotto Alessandro Magno. L'evidenza disponibile induce ad annoverare le locali paludi nel gruppo delle antiche e oggi per lo più estinte ‚foreste allagate‘ mediterranee.
6
Loriedo, Camillo, Flavio Di Leone, Maria Chiara Torti, and Silvia Solaroli. "Il trattamento dei Disturbi di Conversione: studio sull'efficacia di un protocollo ipnotico ultrabreve." IPNOSI, no. 1 (July 2010): 5–19. http://dx.doi.org/10.3280/ipn2010-001001.
Full textAbstract:
L'obiettivo principale di questo studio, randomizzato e controllato, č stato quello di verificare la validitŕ di un intervento di ipnoterapia ultra breve composta da una-tre sedute ipnotiche, specificamente designata al trattamento di patologie che rientrano nei criteri DSM IV previsti per il Disturbo di Conversione. I risultati ottenuti da un gruppo di controllo, composto da 11 pazienti, avviato all'usuale trattamento medico-psichiatrico di supporto sono stati confrontati con quelli ricavati da un gruppo di 12 pazienti assegnati al nostro protocollo. Tutti i pazienti sono stati valutati prima di iniziare i trattamenti (T0) e a distanza di dodici mesi (T1) mediante l'impiego delle seguenti scale di valutazione: Toronto Alexithymia Scale, Somatoform Dissociation Questionnaire, Symptom Check List -90, Illness Behaviour Inventory, Disability Scale, Clinical Global Impressions e la Scala di Valutazione Globale del Funzionamento. Al follow-up, i pazienti afferenti al nostro protocollo hanno dimostrato un miglioramento statisticamente significativo, non soltanto della sintomatologia, ma anche del profilo psicopatologico registrato mentre il gruppo di controllo ha mostrato una pressoché totale assenza di cambiamenti nello stesso periodo. In conclusione, il protocollo ipnotico ultrabreve sembra essere un intervento efficace e specifico, in particolare se adeguatamente programmato e adattato alle caratteristiche del paziente.
7
Luminari, S., M. Lombardo, C. Mammi, M. Bellei, F. Merli, C. Stelitano, A. Lazzaro, R. Marasca, M. Brugiatelli, and M. Federico. "BACOP/FR combination chemotherapy as front-line treatment of follicular lymphoma. A phase II study of the Gruppo Italiano Studio Linfomi (GISL)." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 7571. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.7571.
Full textAbstract:
7571 Background: Doxorubicin, fludarabine and rituximab are all considered active drugs in the treatment of follicular lymphoma (FL). Howevere, the best induction regimen is still matter of debate. In 2003 the GISL started a phase II trial to assess efficacy and tolerability of a combination of bleomycin, adriamycin, ciclophosphamide, vincristine and prednisone (BACOP) followed by fludarabine and rituximab (FR). Methods: To be included in the study pts should have: histologically confirmed diagnosis of FL, stage II-IV disease, age 18–70, active disease. Pts were assessed for t(14:18) by PCR on bone marrow at diagnosis and at time of response assessment. Treatment consisted in three courses of BACOP followed by 4 courses of FR for pts in partial remission (PR) or complete remission with persistent t(14:18) positivity (CRM+). Pts achieving molecular complete remission (CRM-) stopped therapy after BACOP. The main endpoints of the study were overall response rate (CR+PR) (ORR) and failure free survival (FFS). A final accrual of 60 assessable pts was planned, however a faster accrual than expected allowed to enrol 91 pts between May 2003 and Dec 2005. Results: At time of present analysis 61 pts were valuable for final response: Median age was 56 yrs (25–70), male gender 56%, 18% with systemic symptoms, 88% in stage III-IV disease, 13% had elevated LDH and 21% bulky disease. Molecular marker was present in 30 out of 57 pts. 19 pts achieved a CR after three courses of BACOP; four of them, being in CRM- stopped therapy. 28 pts achieved CR with four additional courses of FR. At the end of treatment CR and ORR were 77% and 90% respectively; relatively to pts with molecular marker at diagnosis CRM- was 60%. Toxicity data are available for 57 patients: grade III/IV anemia and neutropenia were observed in two (3%) and 18 (32%) cases respectively; severe infections occurred in two cases, both bacterial pneumonia. After a median follow-up of 17 months (0.5–31) 12 events were observed: Major toxicity, four; non responders, two; relapse, six. Conclusions: BACOP/FR is a feasible and safe regimen for the treatment of patients with FL with promising efficacy. More mature follow-up is required to confirm these preliminary results. No significant financial relationships to disclose.
8
Albert, Umberto, Chiara Picco, Giuseppe Maina, Federica Forner, Eugenio Aguglia, and Filippo Bogetto. "Phenomenology of patients with early- and adult-onset obsessive-compulsive disorder." Epidemiologia e Psichiatria Sociale 11, no. 2 (June 2002): 116–26. http://dx.doi.org/10.1017/s1121189x00005571.
Full textAbstract:
RIASSUNTOScopo – Valutare eventuali differenze nelle caratteristiche sociodemografiche e cliniche (sintomatologia ossessivo–compulsiva, la comorbidità di Asse I e la comorbidità di Asse II) in soggetti adulti con disturbo ossessivo–compulsivo ad esordio precoce (>18 anni) e in eta adulta (≤18 anni). Disegno – Studio clinico controllato. Setting – Servizio per i disturbi depressivi e d'ansia, Dipartimento di Neuroscienze, Università di Torino. Metodo – Sono stati inclusi nello studio 149 pazienti adulti con diagnosi di DOC (DSM–IV) e un punteggio Y–BOCS totale <16.1 soggetti sono stati valutati attraverso un'intervista semi–strutturata diretta ad indagare le caratteristiche socio–demografiche é cliniche. La comorbidita longitudinale di Asse I, secondo i criteri del DSM–IV, è stata valutata attraverso un'intervista clinica strutturata diretta secondo le indicazioni di Othmer & Othmer (1994; 1999): particolare attenzione è stata rivolta alia rilevazione dei disturbi dello spettro ossessivo–compulsivo (Hollander et al, 1996; 1997). Per l'analisi della comorbidita con i disturbi di personalitá è stata utilizzata la Structured Clinical Interview for DSM–IV Axis II Disorders (SCID–II). Risultati – 39 pazienti (26.2%) hanno presentato l'esordio del DOC prima dei 18 anni (early–onset) e 110 pazienti (73.8%) hanno presentato l'esordio del DOC dopo i 18 anni (later–onset). Sono state rilevate differenze significative tra i due gruppi di confronto: i soggetti con esordio precoce presentano una predominanza del sesso maschile, un decorso cronico del disturbo e l'associazione con il disturbo schizotipico di personalità. Conclusioni – Suddividendo il campione secondo l'eta di esordio del disturbo abbiamo rilevato alcune differenze significative nell'espressivita del DOC che indicano una possibile eterogeneita del disturbo, meritevole di ulteriori approfondimenti. In particolare, il rilievo nel gruppo ad esordio precoce di un decorso prevalentemente cronico e soprattutto di una specifica associazione con il disturbo schizotipico di personalita appare significativo ai fini dell'impostazione di specifiche strategic terapeutiche.
9
Meli, Vivienne, and Silvia Romano. "Desertificazione psichica e trasformazione: psicoterapia, arte e immagini con un gruppo di donne rifugiate e vittime di tratta." STUDI JUNGHIANI, no. 50 (January 2020): 54–74. http://dx.doi.org/10.3280/jun2-2019oa8370.
Full textAbstract:
Il nostro articolo è un ampliamento della relazione che abbiamo tenuto del convegno "Art and Psyche: Conference IV. The illuminated imagination" organizzato dallo IAAP (International Association for Analytical Psychology), e svoltosi a Santa Barbara (California) lo scorso aprile. Vorremmo dare un contributo nell'ambito della riflessione sulla potenza evocativa e terapeutica delle immagini e con questo fine abbiamo provato a far dialogare pratica clinica e riflessione teorica, partendo dai contributi sull'argomento di C.G. Jung, D. Kalsched, V. Kast ed altri. Nell'esposizione si alterneranno momenti descrittivi, riguardanti un'esperienza di gruppo di psicoterapia espressiva (arteterapia) con donne rifugiate e vittime di tratta, e momenti di riflessione sulle possibilità che l'arte offre quale lingua comune, che permette di instaurare relazioni immediate, divenendo così strumento di integrazione. I materiali, il processo creativo e l'accoglienza ristabiliscono gradualmente un senso di controllo sugli eventi, andato perso col trauma: lavorare sulle proprie immagini offre delle possibilità riparative, a fronte degli effetti disintegrativi propri dell'esperienza traumatica. In questo modo si supera l'impasse di fronte al quale talvolta ci si trova quando si propone una terapia esclusivamente verbale a persone provenienti da altre culture e portatrici di gravi sofferenze
10
Conte, P. F., M. Bruzzone, F. Carnino, A. Gadducci, R. Algeri, A. Bellini, F. Boccardo, et al. "High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest." Journal of Clinical Oncology 14, no. 2 (February 1996): 351–56. http://dx.doi.org/10.1200/jco.1996.14.2.351.
Full textAbstract:
PURPOSE The aim of the study was to compare high-versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin as primary chemotherapy for suboptimal stage III and IV ovarian cancer. PATIENTS AND METHODS One hundred forty-five patients were randomized to receive six courses of cisplatin 50 or 100 mg/m2 plus epidoxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2. The two treatment arms were well balanced; all patients had greater than 2 cm and 37.2% had greater than 5 cm of residual disease; 29.6% had stage IV disease. RESULTS Patients in the high-dose arm received a double dose-intensity and double total dose of cisplatin. The high-dose regimen induced significantly more episodes of leukopenia (47.8% v 32.8%, P = .05), thrombocytopenia (21.7% v 3.2%, P = .003), anemia (37.6% v 12.5%, P = .002), nephrotoxicity (six v one patient), and neurotoxicity (30.4% v 6.3%, P = .002). There were no significant differences in efficacy in terms of clinical response rate (high-dose 57.5% v low-dose 61.1%), pathologic complete response (CR) (9.6% v 18.1%), median survival times (29 v 24 months), and median progression-free survival (18 v 13 months). CONCLUSION This study shows that doubling the dose-intensity and total dose of cisplatin in combination with epidoxorubicin and cyclophosphamide has significant toxic effects and does not improve clinical outcome in patients with suboptimal ovarian cancer.
11
Del Mastro, Lucia, Marco Venturini, Rita Lionetto, Flavio Carnino, Domenico Guarneri, Luigi Gallo, Antonio Contu, et al. "Accelerated-Intensified Cyclophosphamide, Epirubicin, and Fluorouracil (CEF) Compared With Standard CEF in Metastatic Breast Cancer Patients: Results of a Multicenter, Randomized Phase III Study of the Italian Gruppo Oncologico Nord-Ouest–Mammella Inter Gruppo Group." Journal of Clinical Oncology 19, no. 8 (April 15, 2001): 2213–21. http://dx.doi.org/10.1200/jco.2001.19.8.2213.
Full textAbstract:
PURPOSE: To evaluate whether an accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) chemotherapy regimen with the support of granulocyte colony-stimulating factor (G-CSF) induces a higher activity and efficacy compared with standard CEF in metastatic breast cancer patients. PATIENTS AND METHODS: Stage IV breast cancer patients were randomized to receive as first-line chemotherapy either standard CEF (cyclophosphamide 600 mg/m2, epirubicin 60 mg/m2, and fluorouracil 600 mg/m2) administered every 21 days (CEF21) or accelerated-intensified CEF (cyclophosphamide 1,000 mg/m2, epirubicin 80 mg/m2, and fluorouracil 600 mg/m2) administered every 14 days (HD-CEF14) with the support of G-CSF. Treatment was administered for eight cycles. RESULTS: A total of 151 patients were randomized (74 patients on the CEF21 arm and 77 on the HD-CEF14 arm). In both arms, the median number of administered cycles was eight. The dose-intensity actually administered was 93% and 86% of that planned, in CEF21- and HD-CEF14–treated patients, respectively. Compared with the CEF21 arm, the dose-intensity increase in the HD-CEF14 arm was 80%. Both nonhematologic and hematologic toxicities were higher in the HD-CEF14 arm than in the CEF21 arm. During chemotherapy, four deaths occurred in the HD-CEF14 arm. No difference in overall response rate (complete plus partial responses) was observed: 49% and 51% in the CEF21 and HD-CEF14 arms, respectively (P = .94). A slightly non–statistically significant higher percentage of complete response was observed in the HD-CEF14 arm (20% v 15%). No difference in efficacy was observed. The median time to progression was 14.3 and 12.8 months in the CEF21 and HD-CEF14 arms, respectively (P = .69). Median overall survival was 32.7 and 27.2 months in the CEF21 and HD-CEF14 arms, respectively (P = .16). CONCLUSION: In metastatic breast cancer patients, an 80% increase in dose-intensity of the CEF regimen, obtained by both acceleration and dose intensification, does not improve the activity and the efficacy compared with a standard dose-intensity CEF regimen.
12
Bacigalupo, Andrea, Teresa Lamparelli, Paolo Bruzzi, Stefano Guidi, Paolo Emilio Alessandrino, Paolo di Bartolomeo, Rosa Oneto, et al. "Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO)." Blood 98, no. 10 (November 15, 2001): 2942–47. http://dx.doi.org/10.1182/blood.v98.10.2942.
Full textAbstract:
Abstract One hundred nine patients with hematologic malignancies, undergoing bone marrow transplants (BMT) from unrelated donors, were randomized in 2 consecutive trials to receive or not to receive antithymocyte globulin (ATG) in the conditioning regimen, as follows: (A) 54 patients (median age, 28 years; 39% with advanced disease) were randomized to no ATG (n = 25) versus 7.5 mg/kg rabbit ATG (Thymoglobulin; Sangstat, Lyon, France) (n = 29) ; (B) 55 patients (median age, 31 years, 71% with advanced disease) were randomized to no ATG (n = 28) versus 15 mg/kg rabbit ATG (n = 27). Grade III-IV graft-versus-host disease (GVHD) was diagnosed in 36% versus 41% (P = .8) in the first and in 50% versus 11% (P = .001) in the second trial. Transplant-related mortality (TRM), relapse, and actuarial 3-year survival rates were comparable in both trials. In fact, despite the reduction of GVHD in the second trial, a higher risk for lethal infections (30% vs 7%; P = .02) was seen in the arm given 15 mg/kg ATG. Extensive chronic GVHD developed overall more frequently in patients given no ATG (62% vs 39%;P = .04), as confirmed by multivariate analysis (P = .03). Time to 50 × 109/L platelets was comparable in the first trial (21 vs 24 days; P = .3) and delayed in the ATG arm in the second trial (23 vs 38 days;P = .02). These trials suggest that (1) 15 mg/kg ATG before BMT significantly reduces the risk for grade III-IV acute GVHD, (2) this does not translate to a reduction in TRM because of the increased risk for infections, and (3) though survival is unchanged, extensive chronic GVHD is significantly reduced in patients receiving ATG.
13
Colucci, G., F. Giuliani, R. Mattioli, C. Garufi, R. Mallamaci, G. Pezzella, M. Lopez, and E. Maiello. "FOLFOX-4 + cetuximab in untreated patients with advanced colorectal cancer. A phase II study of the Gruppo Oncologico dell’Italia Meridionale (prot. GOIM 2402)." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 3559. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.3559.
Full textAbstract:
3559 Background: Cetuximab is an IgG monoclonal antibody targeting the EGFR showing to be effective both as single agent or in combination with Irinotecan (CPT-11) or Irinotecan/FU/FA in patients (pts) with EGFR-expressing metastatic colorectal cancer (CRC) in the first and second/subsequent-line setting. The current trial was designed to evaluate the efficacy and the safety of Cetuximab plus Folfox-4 as first -line treatment. The main objective was the percentage of confirmed objective response rate. Methods: Chemonaivepts with non-resectable metastatic CRC and expressing EGFR were treated with Cetuximab (400 mg/m2 week 1 and 250 mg/m2 weekly thereafter) plus Folfox-4 (every 2 weeks: Oxaliplatin 85 mg/m2, day 1; FA 100 mg/m2 2h, simultaneously with OH-P, and FU 400 mg/m2 iv bolus followed by 600 mg/m2 iv for 22h on days 1 and 2). The first evaluation of disease status (Recist criteria) was performed after the first 4 cycles and confirmed after one month. The treatment was continued until a maximum of 12 cycles of chemotherapy; the maintenaice with Cetuximab was permitted. Preliminary results: On the 65 screened pts, 47 (72%) had EGFR-expressing metastatic disease and were enrolled. Their main characteristics were: median Ecog PS 0; median age 66 yrs (range 43–74); main sites of disease: liver 31, lung 12, lymph-nodes 3, others 8. To date twenty-two pts are evaluable for activity and 27 for toxicity; 2 pts are not evaluable and 25 are too early. We observed 16 PR (72.7%), 5 NC (22.7%) and 1 PD (4.6%) for an ORR of 72.7% and a TGCR of 95.4%; the confirmed PR were 15 (68%). To date 2 pts undergone surgery of their metastases both for lung. The main adverse events grade 3/4 (NCI criteria) were: acne-like rush 18.5%, diarrea 7%, nausea/vomiting 4% and anemia 4%. Conclusions: Our preliminary results confirm that the combination of Cetuximab plus Folfox-4 has an high activity and a good safety profile in advanced CRC pts. The study is ongoing. No significant financial relationships to disclose.
14
Gebbia, V., D. Galetta, V. Lorusso, M. Caruso, F. Riccardi, E. Maiello, N. Borsellino, F. Ferraù, G. Colucci, and S. Cinieri. "First-line cisplatin (P) with docetaxel (TXT) or vinorelbine (VNR) in patients with advanced non-small cell lung cancer: A randomized phase II trial of the Gruppo Oncologico Italia Meridionale." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): e19042-e19042. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e19042.
Full textAbstract:
e19042 Background: P-based doublets are considered standard therapy for advanced NSCLC. The GOIM consider P/VNR as a reference treatment. P/TXT doublet has been reported to be active but it's not well known its real impact on QoL in comparison to P/VNR. Methods: Pts received either 6 courses of P/TXT or P/VNR with QoL and safety being the primary endpoints. Secondary endpoint included response rate, TTP, OS, and tolerability. Patients with stage IV/IIIB, age ≤70, and ECOG PS 0–1, were eligible. Sample size was calculated according to Fleming's single-stage procedure. QoL was analysed using the EORTC questionnaire, responses and toxicity according to the RECIST and NCI-CTC criteria. Pts were randomized to: TXT 75 mg/m2 over 60 min followed by P 75 mg/m2 on d1 every 21 d, or VNR 30 mg/m2 on d 1,8 and P 80 mg/m2 on d1 every 21 d. Results: From 12/06 to 3/08 86 pts were enrolled: P/TXT 42pts, M/F 32/10, IIIB/IV 8/34, squamous/not-squamous:13/29, median age 61 (r 41–70); P/VNR 44 pts, M/F 35/9, IIIB/IV 10/33, squamous/not-squamous 14/30, median age 62 (r 44/70). No statistically significant differences were observed in QoL among the two arms. Detailed analysis of side-effects showed no difference among the two regimens with the exception of G3–4 neutropenia and leukopenia with were slightly higher in the P/VNR arm (p=0.02 and p=0.0005 respectively). The use of G- CSF/darbopoietin was more frequent in pts treated with P/VNR than in the P/TXT arm (p=0019). Conclusions: Final data show an equivalence among the two arms regarding QoL and activity but with a slightly more hematological toxicity in the P/VNR arm. Both regimens are to be considered as standards in the treated of advanced NSCLC. [Table: see text]
15
Gerbino, Gianfranca, Giorgio Soragna, Daniele Curci, Derli Fazzari, Maggiorina Bauducco, Aspasia Panunzi, Laura Fabbrini, et al. "La malattia renale cronica: qualità di vita, ansia e depressione in un gruppo di pazienti in fase pre-dialitica." Giornale di Clinica Nefrologica e Dialisi 34 (April 12, 2022): 44–50. http://dx.doi.org/10.33393/gcnd.2022.2400.
Full textAbstract:
Patients with chronic diseases frequently show a marked deterioration in their quality of life (QoL). This paper was aimed at investigating on both the prevalence of psychological disorders and the impact on QoL in patients with chronic renal failure. The survey was conducted on 155 patients, aged 77±11 years, 104/51 M/F, with renal failure on conservative treatment (stages IV-V) referring to Nephrology Unit in Mauriziano Hospital, Turin. 13 of them (8.4%) were aged 30-64 years, 63 (40.6%) were aged 65-79 years and 79 (51%) 80 years and older. Two validated questionnaires were administered, namely the SF-12 (general state of health) and the HADS (anxiety and depression). Sixty-five percent of patients believed to have a low QoL associated with health, finding difficulties in daily life activities. The prevalence of all psychologic disturbances was higher in females (p = 0.09) and in patients with more comorbidities (p = 0.05). Depression was more frequent in elderly (p = 0.05) and in females (p = 0.012). Among patients aged 80 years or over, we found a prevalence rate of 36% for anxiety and of 51% for depression. In all patients, anxiety and depression were strongly associated (p < 0.01). In conclusion, compared to the general population, patients with chronic renal failure have a higher rate of either anxiety or depression, or both, and present with lower QoL scores. Clinical teams dedicated to the management of chronic renal diseases should pursue an interdisciplinary approach to their patients, in order to provide them with a suitable monitoring of QoL and psychological support if needed.
16
Sartori, Riccardo. "Le ragioni per non dirlo. Studio su 17 pazienti maschi adulti omosessuali non dichiarati della provincia di Verona." RIVISTA DI SESSUOLOGIA CLINICA, no. 2 (January 2011): 19–34. http://dx.doi.org/10.3280/rsc2010-002002.
Full textAbstract:
I vantaggi e gli svantaggi di fare coming out in famiglia e al lavoro, per gli omosessuali che vengono allo scoperto e per il gruppo di appartenenza (famiglia e organizzazione), sono ben documentati in letteratura. Mancano invece gli studi che analizzano vantaggi e svantaggi del non fare coming out, probabilmente per la difficoltŕ a reperire soggetti che, per loro natura, vivono nascosti. L'articolo presenta uno studio su 17 pazienti maschi adulti che vivono e lavorano a Verona e non sono dichiarati né in famiglia, né al lavoro, né tra gli amici eterosessuali. Le loro tre diagnosi principali (DSM-IV-TR) - Disturbo Dipendente di Personalitŕ (DDP), Disturbo Ossessivo-Compulsivo (DOC) e Disturbo Narcisistico di Personalitŕ (DNP) - vengono messe in relazione con i tre ordini di ragioni portate dai pazienti per non dichiararsi, esemplificati nei seguenti tre slogan: 1. Vorrei ma non posso (DDP); 2. Dovrei ma non voglio (DOC); 3. Sono fatti miei! (DNP).
17
Giuliani, F., A. Febbraro, R. Addeo, D. Rizzi, E. Maiello, S. Del Prete, S. Pisconti, and G. Colucci. "Sorafenib plus cisplatin and gemcitabine in the treatment of advanced hepatocellular carcinoma (HCC): A phase II study by the Gruppo Oncologico dell'Italia Meridionale (prot. GOIM 2705)." Journal of Clinical Oncology 29, no. 4_suppl (February 1, 2011): 225. http://dx.doi.org/10.1200/jco.2011.29.4_suppl.225.
Full textAbstract:
225 Background: Sorafenib is the standard treatment in advanced HCC. The combination of cisplatin and gemcitabine demonstrated to be active and well tolerated in tumors with a similar poor outcome such as pancreatic and biliary-tract cancers. Considering these data, the GOIM started a phase II trial aiming to evaluate the activity and safety of the combination of sorafenib, gemcitabine and cisplatin in advanced HCC. Methods: Patients affected by advanced HCC, not suitable for surgery or locoregional procedures, with measurable disease (Recist criteria), age ≥ 18 years, clip-score ≤3, ECOG performance status ≥ 60 (K.fsky), adequate bone marrow reserve and renal and hepatic function and who signed written informed consent, were enrolled and received cisplatin 40 mg/mq iv plus gemcitabine 800 mg/mq iv bi-weekly, while sorafenib was orally administrated at the dosage of 400 mg bid continuously. A maximum of 6 cycles of chemotherapy was planned; a maintenance with sorafenib was permitted for not progressing patients. The evaluation of activity was performed every three cycles. A Simon's two stage, two steps study design was applied: at the first step, at least 3 OR had to be observed among the first 28 patients to continue the enrollment. Up to now, 23 patients have been enrolled. Their main characteristics were: sex (male/female) 19/4, median age: 70 yrs, median PS 80,main sites of disease liver 22, lymph nodes 4, lung 2, others 3. Results: Up to now 18 patients are evaluable for activity while 5 are too early. One CR, 3 PR, 6 SD and 8 PRO for an ORR of 4/18 (22%) and a tumor control of 10/18 (55%). Twenty-one patients are evaluable for safety. The main observed side effects (%G1-2/G3-4) (NCI criteria) were: hand-foot skin reaction (HFSR) 9/14, mucositis 9/4, diarrhea 23/4, nausea/vomiting 23/0, leucopenia 23/0, anemia 9/0, thrombocytopenia 19/4, asthenia 14/14, cardiovascular 0/4, others 9/4. Conclusions: Our preliminary data seems to demonstrate that the combination of cisplatin, gemcitabine, and sorafenib is active and well tolerated in advanced HCC patients. The accrual is ongoing. No significant financial relationships to disclose.
18
Sahin, E., C. Cingi, G. Eskiizmir, N. Altintoprak, A. Calli, C. Calli, I. Yilgör, and E. Yilgör. "Biocompatibilità e durata in vivo di cinque nuovi polimeri sintetici testati su coniglio." Acta Otorhinolaryngologica Italica 36, no. 2 (April 2016): 101–6. http://dx.doi.org/10.14639/0392-100x-965.
Full textAbstract:
I materiali alloplastici vengono frequentemente utilizzati negli interventi di chirurgia plastica sul volto, quali la rinoplastica e la chirurgia ricostruttiva del naso. Ad oggi non è stato ancora individuato un materiale alloplastico con caratteristiche ottimali. Il presente studio sperimentale si propone di valutare la risposta tissutale e la resistenza nel tempo di cinque nuovi polimeri proposti come materiali alloplastici. Il presente studio è stato condotto presso un ospedale universitario di terzo livello. Sono state ricavate sei tasche sottocutanee sul dorso di 10 conigli che sono state usate per l’impianto di ciascuno dei polimeri testati più una tasca di controllo. Ciascuna delle tasche è stata escissa congiuntamente al tessuto circostante dopo tre mesi, ed è stata sottoposta ad un esame istopatologico. È stata quindi condotta una valutazione semi quantitativa con focus su neo angiogenesi, infiammazione, fibrosi, formazione di ascessi, presenza di cellule giganti multinucleate contenenti corpi estranei e stato dei polimeri testati. E’ stata inoltre effettuata una valutazione statistica, che per quanto riguarda la comparazione diretta fra la tasca di controllo e i polimeri II, III e IV non ha mostrato differenze significative in merito alla neo vascolarizzazione, all’infiammazione, alla fibrosi, alla presenza di ascessi ed alla presenza di cellule giganti multinucleate. Il polimero I ha invece mostrato un grado di fibrosi inferiore rispetto alla tasca di controllo (p = .027) and V (p = .018), benché le altre variabili prese in considerazione fossero sostanzialmente uguali. L’integrità nel tempo dei polimeri III (9 intatti, uno frammentato) e IV (8 intatti, 2 assenti) è stata migliore di quella ottenuta con gli altri polimeri testati. Questo gruppo di nuovi polimeri può essere considerato interessante per future applicazioni cliniche. Tutti i polimeri hanno mostrato risultati accettabili in termini di risposta dei tessuti, tuttavia i fenomeni di integrazione fibrovascolare sono stati maggiori nel caso dei polimeri II, III e IV. Inoltre la durata nel tempo dei polimeri III e IV è stata la migliore in assoluto.
19
Leveni, Daniela, Damiano Mazzoleni, and Daniele Piacentini. "Cognitive-behavioural group treatment of panic attacks disorder: a description of the results obtained in a public mental health service." Epidemiology and Psychiatric Sciences 8, no. 4 (December 1999): 270–75. http://dx.doi.org/10.1017/s1121189x00008186.
Full textAbstract:
RIASSUNTOScopo - In questo lavoro vengono presentati i risultati, a breve termine e dopo sei mesi di follow-up, ottenuti con un trattamento intensivo di tipo cognitivo-comportamentale di gruppo in soggetti affetti da Disturbo da Attacchi di Panico con o senza Agorafobia secondo i criteri del DSM IV. Disegno e Setting - I risultati si riferiscono ad un campione di 22 soggetti trattati presso il Centro Psico Sociale di Zogno (BG) e valutati attraverso strumenti obiettivi di autovalutazione, inerenti sia la soddisfazione di vita (SF/36) che l'and amento sintomatologico (PAAAS, MSPS, STAI-X1, STAI-X2). I dati ottenuti sono indicativi di significativi miglioramenti al termine del trattamento. Sono in corso ulteriori follow-up per valutare il mantenimento nel tempo dei risultati raggiunti. Conclusioni -Il risultato più importante appare comunque la dimostrazione che anche in un Servizio pubblico italiano di salute mentale, come in molti paesi esteri, è stato possibile trattare pazienti affetti da Disturbi d'Ansia con tecniche di dimostrata efficacia e relativamente a basso costo e soprattutto che è possibile introdurre nell'attività clinica routinaria indicatori obiettivi di esito.
20
Di Nicola, Massimo, Liliana Devizzi, Alessandro Rambaldi, Manuela Zanni, Fabio Benedetti, Caterina Patti, Tiziano Barbui, Corrado Tarella, and Alessandro M. Gianni. "Efficacy of High-Dose Sequential Chemotherapy and Autograft for Transformed Non Hodgkin’s B Cell Lymphoma: Results of a Retrospective Analysis from GITIL (Gruppo Italiano Terapie Innovative nei Linfomi)." Blood 110, no. 11 (November 16, 2007): 3440. http://dx.doi.org/10.1182/blood.v110.11.3440.3440.
Full textAbstract:
Abstract Background - Follicular lymphoma (FL) transforms in a more aggressive lymphoma in 25–60% of patients representing the outgrowth of a more malignant subclone. Transformation is usually associated to a rapidly progressive clinical course, refractoriness to treatment, and short survival. To define the impact of high dose sequential (HDS) therapy and peripheral blood stem cell (PBSC) autograft on outcome of transformed FL (TFL), we analyzed a consecutive series of 66 pts with a confirmed diagnosis of TFL registered at the GITIL centers from March 1988 to September 2004 and treated with the HDS regimen. Methods - Biopsy-proven histological transformation (HT) in diffuse large B cell lymphoma (DLBCL) was observed at diagnosis (n=24; 36%) or at relapse after a treatment for FL (n= 42; 64%). Main patient characteristics were as follows: male/female 36/30; median age 51 yrs (range 33–66), stage I-II/III-IV 8/58, IPI score 0–1/≥2 28/38. HDS regimen included: i. 3 APO or 3 DHAP courses (for patients relapsed after anthracycline-containing regimens); ii. sequential administration of hd-CTX (7g/mq), hd-Ara-C, (2g/mq q12h for 6 days) hd-Etoposide (2.4 g/mq), with PBSC harvests following hd-CY and hd-Ara-C; iii. myeloablative regimen with hd-Mitoxantrone/L-Pam (n=28) or BEAM (n=28 pts who could not receive additional anthracycline), or TBI-PAM (n=3); iv. PBSC autograft; v. consolidation radiotherapy on bulky disease. From January 1999, hd-CTX and hd-Ara-C has been supplemented with Rituximab (RHDS; n=34) with in-vivo purging intent. Results - Overall 59 patients achieved a complete remission (CR; 89%), 1 patient responded partially and underwent allogeniec bone marrow transplantation, 6 patients died for progressive disease while on therapy (PD; 9%). With a median follow-up of 67 months (range 23–170), 42 patients are alive (63.6%), 24 patients relapsed and died for progressive disease (n= 23) or toxicity (n= 1). Five-year event free survival (EFS) and overall survival (OS) are 53.0% and 63.6%, respectively. No significant differences in OS and EFS were observed between patients with HT at diagnosis or at relapse, with IPI O-1 vs IPI >2. Of note, pts treated with R-HDS showed an improved clinical outcome (OS: 76% vs. 50%; EFS: 67.6 vs. 37.5 respectively), with a large difference that did not reach statistical significance because of the limited number of patients. Conclusion - Our data strongly suggest that HDS regimen, in particular when supplemented with rituximab (R-HDS), is a very effective regimen in transformed B cell lymphoma.
21
Maina, Giuseppe, Patrizia Vaschetto, Simona Ziero, Rossella Di Lorenzo, and Filippo Bogetto. "The post partum as specific risk factor for the onset of obsessive-compulsive disorder: clinical- controlled study." Epidemiologia e Psichiatria Sociale 10, no. 2 (June 2001): 90–95. http://dx.doi.org/10.1017/s1121189x00005169.
Full textAbstract:
RIASSUNTOScopo – Lo studio si propone di indagare, tra gli eventi psicosociali stressanti, l'esistenza di un fattore di rischio specifico per l'esordio del disturbo ossessivo-compulsivo nelle donne (DOC). Disegno – Studio clinico controllato. Setting – Servizio per i disturbi depressivi e d'ansia, Clinica Psichiatrica, Università di Torino. Metodo – Sono state inserite nella ricerca 29 pazienti di sesso femminile con diagnosi attuale di DOC secondo i criteri del DSM-IV. Tale popolazione è stata confrontata con 2 gruppi di controllo: 29 donne sane appaiate per caratteristiche sociodemografiche alle pazienti ossessive e 29 pazienti di sesso femminile con diagnosi attuale di bulimia nervosa appaiate per età, età d'esordio, scolarita e stato civile al gruppo di studio. A tutte le donne incluse nell'indagine è stata somministrata l'lntervista Clinica Strutturata per il DSM III-R (SCID) per la valutazione dei disturbi di Asse I e I'Interview for Recent Life Event di Paykel per I'individuazione dei life-events nei 12 mesi precedenti l'esordio del disturbo (e negli ultimi 12 mesi per le donne sane). Inoltre, alle pazienti ossessive è stata somministrata la Yale- Brown Obsessive Compulsive Scale (Y-BOCS) e alle pazienti bulimiche la Eating Disorder Inventory(EDI). Risultati – Sia la frequenza che la gravità degli eventi psicosociali stressanti non sono risultate significativamente differenti nei tre gruppi. La valutazione della prevalenza dei singoli eventi ha messo in evidenza che il life-event “nascita di un figlio vivo per la madre” era significativamente più frequente nelle pazienti ossessive. Conclusioni – Lo studio ribadisce in primo luogo quanto avevamo osservato in una precedente ricerca: tra gli eventi psicosociali stressanti, riscontrati nell'anno precedente l'insorgenza del DOC, solo il post partum costituisce un fattore di rischio per l'esordio del disturbo nella popolazione femminile rispetto ai controlli sani. In secondo luogo, tale ricerca porta ulteriori evidenze a favore dell'importanza e specificità di questa associazione, mostrando che non in tutte le patologie psichiatriche il post partum è un fattore di rischio per l'esordio.
22
Todeschini, Giuseppe, Paolo Corradini, Sergio Cortelazzo, Alessandro Rambaldi, Andrea Gallamini, Fabio Benedetti, Andres Ferreri, et al. "Hyperchidam Verona897 Regimen Is Effective in Treatment of Advanced Peripheral T Cell Lymphoma (PTCL): The GITIL Experience in 33 Cases." Blood 110, no. 11 (November 16, 2007): 4465. http://dx.doi.org/10.1182/blood.v110.11.4465.4465.
Full textAbstract:
Abstract Background. Peripheral T cell Lymphoma (PTCL) represent a major therapeutic challenge. In the previous Verona experience (Todeschini G et al. Cancer2005;104:555–560), the novel intensive regimen HyperCHiDAM Verona897 (high-dose IV MTX 2 g/sqm 400 sqm bolus, 1600 sqm CI day 1 with IV leucovorin rescue; hyperfractionated IV CTX 300 mg/sqm Q12h, dd 2–4; high-dose IV AraC 2g/sqm Q12h, dd 2-4; plus G-CSF) achieved salutary results in refractory/relapsed aggressive lymphomas, in particular in PTCL. Supportive measures included hydratation 3000 ml/sqm/day, antimicrobial prophylaxis comprising oral ciprofloxacin, itraconazole, trimethoprim/sulfamethoxazole. CMV antigenemia (pp65) was monitored 2 times a week. Patients. Following these results, 7 centers belonging to the Italian co-operative group GITIL (Gruppo Italiano Terapie Innovative Linfomi) treated with 2 cycles of HyperCHiDAM Verona897, 33 patients affected by PTCL (17 upfront, 16 refractory/relapsed) followed in the majority of cases by stem cell transplant. Patients: M/F 21/12, median age 49 (19–63) years; histology: PTCL-NOS 15, ALCL ALK-negative 9, EALTC 4, AIL 3, T-NK nasal 1, Angiocentric 1; stage IV 19/33 (57.5%), bone-marrow positive 10/33 (30.3%), extranodal involvement 24/33 (72.7%), high LDH 18/33 (54.5%). Seven patients needing urgent treatment were treated before HyperCHiDAM with 1 cycle of Campath-CHOP (4 patients) or CHOP + L-ASE (3 patients). Results. Upfront patients: after 2 cycles of HyperCHiDAM, CR were 82.3% (14/17), early toxic deaths 0 (1 late toxic death occurred after SCT, due to CMV pneumonia), relapses 3/14. With a median follow-up of 21 months (3–90+), 11/17 (64.7%) patients are disease-free, 10 in first CR, 1 after rescue with stem cell transplant. Three of the CCR patients received HyperCHiDAM alone. Refractory/relapsed patients: CR were 5/16 (31.2%), CCR 4/16 (25%), with a median follow-up of 24 months (5–64+). The progression-free survival was significantly superior in upfront patients (p=0.036). Overall, toxic deaths were 3/33 (9%), 1/17 (5.8%) in upfront and 2/16 (12.5%) in refractory/relapsed patients. One patient had major cerebellar toxicity. Conclusions. The intensive regimen HyperCHiDAM Verona897 is effective in inducing CR in aggressive PTCL, in particular as upfront therapy. The intensiveness of this treatment requires a careful supportive therapy. Following these results, HyperCHiDAM has been included in a national trial for treatment of PTCL, after 2 cycles of Campath-CHOP and before stem cell transplant (allogeneic or autologous depending on the availability of an HLA-matched sibling). The co-operative study is recruiting.
23
Paccagnella, A., A. Orlando, C. Marchiori, P. L. Zorat, G. Cavaniglia, V. C. Sileni, A. Jirillo, et al. "Phase III Trial of Initial Chemotherapy in Stage III or IV Head and Neck Cancers: a Study by the Gruppo di Studio sui Tumori della Testa e del Collo." JNCI Journal of the National Cancer Institute 86, no. 4 (February 16, 1994): 265–72. http://dx.doi.org/10.1093/jnci/86.4.265.
Full text
24
Mitry, Emmanuel, Anthony L. A. Fields, Harry Bleiberg, Roberto Labianca, Guillaume Portier, Dongsheng Tu, Donato Nitti, et al. "Adjuvant Chemotherapy After Potentially Curative Resection of Metastases From Colorectal Cancer: A Pooled Analysis of Two Randomized Trials." Journal of Clinical Oncology 26, no. 30 (October 20, 2008): 4906–11. http://dx.doi.org/10.1200/jco.2008.17.3781.
Full textAbstract:
Purpose Adjuvant systemic chemotherapy administered after surgical resection of colorectal cancer metastases may reduce the risk of recurrence and improve survival, but its benefit has never been demonstrated. Two phase III trials (Fédération Francophone de Cancérologie Digestive [FFCD] Trial 9002 and the European Organisation for Research and Treatment of Cancer/National Cancer Institute of Canada Clinical Trials Group/Gruppo Italiano di Valutazione Interventi in Oncologia [ENG] trial) used a similar design and showed a trend favoring adjuvant chemotherapy, but both had to close prematurely because of slow accrual, thus lacking the statistical power to demonstrate the predefined difference in survival. We report here a pooled analysis based on individual data from these two trials. Patients and Methods After complete resection of colorectal liver or lung metastases, patients were randomly assigned to chemotherapy (CT arm; fluorouracil [FU] 400 mg/m2 administered intravenously [IV] once daily plus dl-leucovorin 200 mg/m2 [FFCD] × 5 days or FU 370 mg/m2 plus l-leucovorin 100 mg/m2 IV × 5 days [ENG] for six cycles at 28-day intervals) or to surgery alone (S arm). Results A total of 278 patients (CT, n = 138; S, n = 140) were included in the pooled analysis. Median progression-free survival was 27.9 months in the CT arm as compared with 18.8 months in the S arm (hazard ratio = 1.32; 95% CI, 1.00 to 1.76; P = .058). Median overall survival was 62.2 months in the CT arm compared with 47.3 months in the S arm (hazard ratio = 1.32; 95% CI, 0.95 to 1.82; P = .095). Adjuvant chemotherapy was independently associated with both progression-free survival and overall survival in multivariable analysis. Conclusion This pooled analysis shows a marginal statistical significance in favor of adjuvant chemotherapy with an FU bolus–based regimen after complete resection of colorectal cancer metastases.
25
Roth, Roman Ernst. "Black-gloss wares from the acropolis of Capena (La Civitucola, provincia di Roma)." Papers of the British School at Rome 74 (November 2006): 119–62. http://dx.doi.org/10.1017/s006824620000324x.
Full textAbstract:
CERAMICA A VERNICE NERA DALL'ACROPOLI DI CAPENA (LA CIVITUCOLA, PROVINCIA DI ROMA)Con questo articolo si pubblica la ceramica a vernice nera scoperta durante una serie di scavi condotti alla Civitucola dal Gruppo Archeologico Romano durante i primi anni Novanta del secolo scorso. Il materiale (ca. 500 frammenti diagnostici) coprono un arco cronologico di oltre 200 anni, dagli inizi del IV al tardo II secolo a.C, con un picco di presenze durante i decenni centrali di quest'ultimo secolo. Tale aspetto riguarda sia la ceramica a vernice nera importata, sia quella destinata alla commercializzazione locale, che, piuttosto che sovrapporsi nei dettagli morfalogici, tendi a ricorrere in forme specifiche con corpo ceramico distinto. Di particolare interesse a questo riguardo è la pasta principale prodotta localmente (pasta n. I). La ceramica prodotta con questo pasta combina gli stili tradizionali di Capena con elementi comunemente riscontrati nella ceramica a vernice nera in altre parti dell'Italia centrale, ma senza copiare lo stile dei tipi principali della ceramica importata (pasta V). L'articolo conclude con il suggerimento che questi modelli, paragonabili con altre situazioni in Italia centrale, siano studiati nell'ambito del contesto della crescente diversificazione culturale a livello regionale all'interno del più ampio processo storico della romanizzazione d'Italia.
26
Bruno, B., M. Rotta, F. Patriarca, D. Mattei, B. Allione, F. Carnevale-Schianca, A. Rambaldi, et al. "A Prospective Phase II Study on Tandem Autografting-Nonmyeloablative Allografting for Newly Diagnosed Myeloma: Final Results of the Gruppo Italiano Trapianto Midollo Osseo." Blood 110, no. 11 (November 16, 2007): 3026. http://dx.doi.org/10.1182/blood.v110.11.3026.3026.
Full textAbstract:
Abstract The development of nonmyeloablative conditionings has recently reduced the transplant-related mortality (TRM) and extended the eligible age for transplantation up to 65–70 years. From January 2000 to June 2005, 106 newly diagnosed patients younger than 65 years were enrolled in a prospective phase II study at 15 Italian Centers. Fifty-eight were also previously described in a comparison of autografting with allografting based on a genetic randomisation (Bruno et al. N Engl J Med 2007). Here we report on a larger GITMO experience with a longer follow-up. Induction chemotherapy consisted of VAD-based regimens, followed by a cytoreductive autograft with melphalan 200 mg/m2, and by a non-myeloablative 2 Gy TBI-based allograft from an HLA-identical sibling. Graft-vs-host disease (GVHD) prophylaxis included cyclosporin and mycophenolate mofetil. Primary endpoints were overall (OS) and event-free (EFS) survivals. Secondary endpoint was TRM. One-hundred-two (96%) patients, median age 54 (30–65), completed the tandem program whereas 4 withdrew their consent. After a median follow-up of 54 (21–94) months, OS was not reached and median EFS was 35 (31–56) months post-transplant. Incidences of acute grade II-IV GHVD and extensive chronic GVHD were 40% and 50% respectively. Fourteen (13%) patients died from TRM, 14 (13%) from disease progression, 2 from lung cancer (2%) and 1 from lymphoma (1%). Overall response, defined as complete (CR) and partial remission, was 91% (93/102), with 53 patients achieving CR. Overall 39/102 patients relapsed, however only 8/53 of those who reached CR post-transplant. By multivariate-analysis disease response prior to allografting was significantly associated with longer OS (HR 0.27, CI 0.09–0.80, p<0.018) and longer EFS (HR 0.23, CI 0.11–0.49, p<0.001). Interestingly, chronic GVHD was not correlated with either the achievement of post-transplant CR (HR 0.87, CI 0.45–1.65, p<0.66) or its duration (HR 0.79, CI 0.45–1.40, p<0.42). Presence of del(13) was evaluated only in a subset of 39 patients: 13 carried del(13) and 26 did not. OS was not reached in the patients without del(13) and was 52 months in patients with del(13) (p=0.32), however EFS was not reached in the patients without del(13) whereas was 27 months for patients with del(13) (p=0.04). Given the encouraging results, the design of prospective studies that incorporate new drugs to cytoreduce the disease pre-transplant and enhance graft-vs.-myeloma are warranted to lower relapse rates and improve clinical outcomes.
27
Rambaldi, Alessandro, Anna Grassi, Maria Caterina Micò, Alessandro Busca, Benedetto Bruno, Irene Cavattoni, Stella Santarone, et al. "Randomized Trial of Busulfan with Cyclophosphamide Versus Busulfan with Fludarabine As Preparative Regimen to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia: A Study from the Gruppo Italiano Trapianto Midollo Osseo (GITMO)." Blood 124, no. 21 (December 6, 2014): 727. http://dx.doi.org/10.1182/blood.v124.21.727.727.
Full textAbstract:
Abstract Background The combination of a myeloablative dose of intravenous (iv) busulfan with cyclophosphamide is the standard preparative regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in acute myeloid leukemia (AML) patients. However, in patients older than 40 years, this conditioning can be associated to high non relapse mortality (NRM). A similar myeloablative dose of busulfan combined to fludarabine was found associated to a lower NRM in older AML (Alatrash, BBMT 2011). Patients and study design The Gruppo Italiano Trapianto Midollo Osseo (GITMO) conducted a Phase III, randomized, multicenter, trial to compare the standard myeloablative combination of iv busulfan (Busilvex®, Pierre Fabre, Boulogne, France) at a dose of 0.8 mg/kg/6h over two hours infusion for 4 consecutive days (16 doses), for a total dose of 12.8 mg/kg, in combination with cyclophosphamide at the dose of 60 mg/kg/day for 2 consecutive days for a total dose of 120 mg/kg (BUCY2 arm) or fludarabine at the dose of 40 mg/m2/day for 4 consecutive days, for a total dose of 160 mg/m2 (BUFLU arm). Eligible were patients with a diagnosis of AML in 1st or 2nd complete remission (CR) with an age ≥40 and ≤ 65 years, and the availability of an HLA compatible sibling or unrelated donor as defined by molecular high-resolution typing (4 digits) of the HLA gene loci class I (HLA- A, B, and C) and class II (DRB1). Excluded were patients with a t(15;17) or PML/RARα positive APL or with a t(8;21)(q22;q22) or an inv(16) or t(16;16)(p13;q22) positive AML in 1st CR. The GvHD prophylaxis was based on conventional Cyclosporine A and Methotrexate. In case of unrelated donors, anti Thymocyte Globulin (Thymoglobuline®, Sanofi-Aventis) was given at a total dose of 5 mg/kg (or 7.5 mg/kg, in case of HLA acceptable disparity) (one antigen/allele disparity in class I, or one allele disparity in class II). The primary study end-point was the one-year NRM using an intent-to-treat analysis. The required sample size was calculated assuming that the one-year NRM would have been halved (from 25% to 12.5%) in the BUFLU arm. The cumulative incidence of NRM was estimated by considering relapse as a competing event. All outcomes were evaluated from the date of transplantation. The study was approved by the Institutional Review Boards of each center. Results From July 2008 to February 2013, 25 centers in Italy and 1 in Israel, enrolled 245 patients who were randomly assigned to BUCY2 (n=121) or BUFLU (n=124), stratified according to donor type and remission (1st vs. 2nd or more). The main clinical features (balanced between the randomization arms) were as follows: the median age was 50 years, 209 patients (85%) were in 1st and 36 (15%) in 2ndCR and the ELN risk subgroups were good (11%), intermediate-1 (46%), intermediate-2 (20%) and adverse (23%). The donor was a sibling related (n= 112, 46%) or matched unrelated (n= 133, 54%) while the stem cell graft was the peripheral blood (PB, n= 168, 69%) or the bone marrow (BM, n= 77, 31%). The overall survival rate in the BUCY2 and BUFLU arm was 71% vs. 78% at 1 year, 65% vs. 62 % at 2 years and 56% vs. 57% at 5 years, respectively (P=ns). A non-significant lower incidence of relapse was documented in the BUCY2 vs. the BUFLU arm being 20.7% vs. 24.2% at 1 year, 25.6% vs. 29% at 2 years and 28.9 vs. 32.3 at 5 years, respectively. On the contrary, at 1 year, the overall NRM in the BUCY2 arm was 17.4% vs. 7.3% in the BUFLU (Gray Test P=0.02). At 2 years and throughout the study, the same significantly different NRM was observed between study arms being respectively 18.2% vs. 8.9% and 19% vs. 9.7% (Gray Test P=0.03) (Figure 1). Causes of NRM in the BUCY2/BUFLU arms were: infections 8/6, organ failures 9/0, GvHD 5/3, hemorrhage 1/1, others 0/2. All in all, at 1, 2 and 5 years the leukemia free survival of the BUCY2 and BUFLU arm was similar being 62% vs. 69%, 56% vs. 62% and 50% vs. 56%, respectively (P=ns) (Figure 2). The number of patients with grade III-IV acute GvHD was higher in the BUCY2 arm (P= 0.02). There were no significant between-group differences in the incidence of chronic GvHD. Conclusion In AML patients older than 40 years, the reduced toxicity conditioning with iv BUFLU significantly reduced the NRM compared to BUCY2. The increased incidence of leukemia relapse in the BUFLU arm was not associated with a detrimental effect on overall and leukemia free survival. (Funded by a grant from the Agenzia Italiana per il Farmaco (AIFA), ClinicalTrial.gov Identifier: NCT1191957). Figure 1 Figure 1. Figure 2 Figure 2. Disclosures Rambaldi: Pierre Fabre Pharma: Consultancy.
28
Merli, Francesco, Stefano Luminari, Fiorella Ilariucci, Caterina Stelitano, Mario Petrini, Nicola Di Renzo, Francesco Angrilli, Angelo Michele Carella, Elisa Barbolini, and Massimo Federico. "Rituximab Plus Hypercvad Alternating with High Dose Methotrexate and Cytarabine for Patients with Newly Diagnosed Mantle Cell Lymphoma. A Multicenter Trial from GISL." Blood 112, no. 11 (November 16, 2008): 3050. http://dx.doi.org/10.1182/blood.v112.11.3050.3050.
Full textAbstract:
Abstract BACKGROUND. Rituximab plus HyperCVAD alternating with High Dose Methotrexate and Cytarabine (R-HCVAD) has been tested in patients with newly diagnosed Mantle Cell Lymphoma (MCL) with promising results (Romaguera et al. JCO 2005). In 2005 the Gruppo Italiano Studio Linfomi (GISL) started a phase II multicenter study investigating clinical activity and toxicity of R-HCVAD in a similar group of patients. PATIENTS AND METHODS. To be included in the trial patients must have histologically confirmed diagnosis of MCL, be younger than 70 years, have adequate organ function. Chemotherapy consisted of rituximab plus fractionated cyclophosphamide, vincristine, doxorubicine, and dexamethasone(considered one cycle) alternating every 21 days with rituximab plus high dose methotrexate-cytarabine (considered one cycle) for a total of eight cycles per the MD Anderson protocol. Patients with baseline PCR positivity for t(11;14) on bone marrow (BM) had to perform PCR assessment of BM at evaluation of response and during follow-up. Only patients achieving partial response (PR) were to be addressed to HDC followed by ASCT. RESULTS. Thirty-two patients were enrolled. There were 23 males and 9 females; median age was 54 yrs (29 to 66), 80% were in stage IV, 50% and 71% had Gastrointestinal (GI) and BM involvement, respectively; PCR for t(11;14) was positive on BM in 51% of cases. Seven patients did not complete treatment due to toxicity; of these, two patients died (one with septic shock at cycle 1, one with pulmonary aspergillosis at cycle 4), one patient had thrombosis of central line extended to right atrium at cycle 1, one had grade IV skin reaction at cycle 3, one had a severe pneumonia at cycle 1, two had persistent grade IV hematological toxicity after cycle 1 and 5, respectively. All patients had grade III–IV hematological toxicity. Response was assessed in 17 patients with 16 CR and 1 PR. PCR for t(11;14) negativity on BM was achieved in 4/9 patients after cycle 4 and in 8/9 after cycle 8. After a median follow-up of 24 months 1 patient progressed at 6 months and 1 patient relapsed after 26 months of follow-up. Two-year Failure Free Survival (FFS) was 75% (IC95% 53 to 87) and 2 year Disease Free Survival was 93%(IC95% 59–99). CONCLUSIONS. Though longer follow-up is needed R-HCVAD regimen used in our multicenter setting confirmed high efficacy in terms of response (both clinical and molecular) and FFS. However the regimen was associated to a severe toxicity profile that caused treatment discontinuation in several patients and that may limit its use in the clinical setting.
29
Federico, Massimo, Stefano Luminari, Emilio Iannitto, Giuseppe Polimeno, Luigi Marcheselli, Antonella Montanini, Antonio La Sala, et al. "ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial." Journal of Clinical Oncology 27, no. 5 (February 10, 2009): 805–11. http://dx.doi.org/10.1200/jco.2008.17.0910.
Full textAbstract:
Purpose To compare doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) versus bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) versus cyclophosphamide, lomustine, vindesine, melphalan, prednisone, epidoxirubicin, vincristine, procarbazine, vinblastine, and bleomycin (COPPEBVCAD; CEC) for advanced Hodgkin's lymphoma (HL). Patients and Methods Three hundred seven patients with advanced HL (stage IIB, III, and IV) were randomly assigned to receive six courses of ABVD, four escalated plus two standard courses of BEACOPP, or six courses of CEC, plus a limited radiation therapy program. Results After a median follow-up of 41 months, BEACOPP resulted in a superior progression-free survival (PFS), with a significant reduction in risk of progression (hazard ratio [HR] = 0.50) compared with ABVD. No differences between BEACOPP and CEC, or CEC and ABVD were observed. The 5-year PFS was 68% (95% CI, 56% to 78%), 81% (95% CI, 70% to 89%), and 78% (95% CI, 68% to 86%), for ABVD, BEACOPP, and CEC, respectively (BEACOPP v ABVD, P = .038; CEC v ABVD and BEACOPP v CEC, P = not significant [NS]). The 5-year overall survival was 84% (95% CI, 69% to 92%), 92% (95% CI, 84% to 96%), and 91% (95% CI, 81% to 96%) for ABVD, BEACOPP, and CEC, respectively (P = NS). BEACOPP and CEC resulted in higher rates of grade 3-4 neutropenia than ABVD (P = .016); BEACOPP was associated with higher rates of severe infections than ABVD and CEC (P = .003). Conclusion As adopted in this study BEACOPP is associated with a significantly improved PFS compared with ABVD, with a predictable higher acute toxicity.
30
Santo, A., G. Genestreti, A. Terzi, P. Azzoni, O. Caffo, E. Galligioni, A. Cipriani, E. Binato, G. Cartei, and G. Cetto. "Preliminary results of G versus GViElC: A phase III trial of gemcitabine associated to vindesine or gemcitabine alone in elderly or poor performance patients with advanced non-small cell lung cancer (NSCLC)." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 17083. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.17083.
Full textAbstract:
17083 Background: Monochemotherapy with gemcitabine (GEM) or vinorelbine is considered the standard treatment in elderly or poor performance (PS) patients (pts) with advanced NSCLC. Many topics report a synergic enhancement of antitumor effect of GEM if associated to Vindesine (VDS). The aim of this study is to evaluate if GEM combined to VDS produces an advantage in terms of overall survival (OS) compared to GEM alone without enhancement of toxicity. Methods: Chemonaive pts with stage IIIB/IV NSCLC, aged ≥ 70 years with PS < 2 or aged < 70 years with PS > 2 were enrolled. Pts were randomized to receive either GEM 1200 mg/m2 day 1 and 8 every 21 days for three cycles (arm 1) or GEM 1000 mg/m2 and VDS 3 mg/m2 (max dose 5 mg) both drugs infused on day 1 and 8 every 21 days for three cycles (arm 2). Pts of both arms received other three cycles in case of responsive or stable disease. Overall survival (OS) was the primary end-point, secondary end-points were time-to-progression and toxicity. First interim analysis was planned at 120 pts enrolled. Results: From May 2002 to December 2005, 107 pts from 13 Italian institutions were enrolled. Their characteristics are: 24 stage IIIB and 83 stage IV, 79 pts with ≥ 70 years (ECOG PS 0–1) and 28 pts with < 70 years (ECOG PS > 2). In arm 1 there were enrolled 55 pts while 52 pts in arm 2: both arms were well balanced with pts characteristics. Conclusions: The enrollment of this phase III trial is ongoing: we are achieving first step for an interim analysis to assess if GEM associated to VDS produces an advantage in terms of OS compared to standard treatment as GEM in monochemotherapy without toxicity enhancement. (Supported by GIVOP: Gruppo Interdisciplinare Veronese di Oncologia Polmonare). No significant financial relationships to disclose.
31
Ladetto, Marco, Sonia Vallet, Paolo Corradini, Fabio Benedetti, Umberto Vitolo, Maurizio Martelli, Vincenzo Callea, et al. "Long-Term Outcome of High-Dose Sequential Chemotherapy with Autografting (i-HDS) in Follicular Lymphoma at Diagnosis: An Update of the Prospective Multicenter Consecutive Trial of the "Gruppo Italiano Trapianto Di Midollo Osseo" (Gitmo)." Blood 104, no. 11 (November 16, 2004): 903. http://dx.doi.org/10.1182/blood.v104.11.903.903.
Full textAbstract:
Abstract Introduction. i-HDS is a promising though experimental treatment for FL patients at diagnosis. We have published that i-HDS is feasible also in the context of a multicenter trial with limited toxicity and promising results (Ladetto et al, Blood, 2002). This analysis is an update at 42 months from the previous closing date. Particular attention has been devoted to late toxicities and outcome according to molecular remission (MR). Patients and methods. 92 untreated patients aged 18–60 years with stage III-IV FL requiring treatment were enrolled by 20 Italian centers between 1997 and 1999 and evaluated on an intention-to-treat basis. Inclusion criteria have been previosly described. Clinical features at diagnosis were: Ann Arbor stage IV: 84%; BM involvement: 80%; extranodal and extra-BM disease: 55%; bulky mass: 51%; elevated serum LDH: 37%; "B" symptoms: 30%; leukemic disease: 12%; aaIPI ≥ 2: 37%. The i-HDS schedule included 2APO, 2DHAP, Etoposide 2g/sqm, Methotrexate 8g/sqm and Cyclophosphamide 7g/sqm with PBPC collection. The myeloablative regimen was Mitoxantrone 60mg/sqm + Melphalan 180mg/sqm followed by 5–8x106 CD34+ cells/kg. Minimal residual disease analysis with the bcl-2/IgH rearrangement was available in 47% of patients. Results: 87% of patients completed the planned treatment. CR rate was 88%. Currently the median follow-up is 62 months. Late toxic effects included five myelodysplastic syndromes and /or secondary leukemias (MDS/2AL) all occurring within two years from the end of treatment. In 4 of 5 cases MDS/2AML occurred in subjects already re-treated for disease relapse. Two fatal solid tumors (one gastric cancer and one lung cancer) were also recorded. Long-term hematopoietic fuction was satisfactory in all patients not developing MDS/2AML. Heart failure occurred in three patients, always manageable with oral medical treatment. The projected overall survival and progression-free survival (PFS) at 7,5 years are 74% and 56%. Notably, following i-HDS, patients with aaIPI≥2 had an outcome comparable to those with aaIPI ≤ 1 (p=NS). Attainement of MR in the first year following i-HDS was highly predictive even for the long term outcome. Among patients achieving MR the relapse rate (RR) was 13% while in those failing to achieve MR was 81% (p<0001). Conclusions. This long-term analysis indicates the following: a) i-HDS allows long-term PFS in 56% of advanced FL patients regardless of the aaIPI. This result compares favorably with those achieved with Rituximab-free non-intensified therapy at least for high-risk patients; b) MR achievement is a powerful indicator for prolonged PFS; c) although severe side effects occurred in this series, relapse remains the major cause of treatment failure. Thus, treatment implementation is required. Rituximab inclusion is probably one of the most feasible approaches, suitable for multicenter trials. The new GITMO trial, comparing CHOP vs i-HDS (both supplemented with Rituximab), currently ongoing for high-risk (aaIPI≥2) FL patients, will help clarifying wheter dose-intensification has still a role in the monoclonal antibody era.
32
Galetta, Domenico, Salvatore Pisconti, Saverio Cinieri, Vittorio Gebbia, Alessandro Morabito, Nicolo Borsellino, Evaristo Maiello, et al. "First-line pemetrexed plus cisplatin followed by maintenance pemetrexed versus carboplatin-paclitaxel plus bevacizumab followed by maintenance bevacizumab (ERACLE) in advanced nonsquamous NSCLC: A quality-of-life-oriented, multicenter randomized phase III trial of the GOIM (Gruppo Oncologico Italia Meridionale)." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 8071. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.8071.
Full textAbstract:
8071 Background: In absence of oncogenic driver chemotherapy (CT) for advanced non-squamous non-small cell lung cancer (NS-NSCLC) remains palliative with similar efficacy and survival among different regimens. Histotype, maintenance therapy (m) and quality of life (QoL) have been explored to improve patients (pts) outcome. ERACLE trial (NCT01303926), a QoL-oriented phase III trial was designed to compare the QoL for two CT regimens. Methods: Pts with stage IIIB/IV NS-NSCLC (ECOG 0/1) were randomized (1:1) to receive first-line CT. ARM A received 6 cycles of Cisplatin (C) (75 mg/m2) - Pemetrexed (P) (500 mg/m2) q3w, followed by mP (500 mg/m2) while ARM B received Carboplatin (Cb) AUC 6 - Paclitaxel (T) 200 mg/m2plus Bevacizumab (Be) 15 mg/kg q3w for 6 cycles and mBe 15 mg/kg. Both treatments were administered until progression, unacceptable toxicity or death. Stratification was based on Study Centre and disease stage. Co-Primary endpoints were EQ5D Index (EQ5D-I) and EQ5D-VAS (Euro-QoL questionnaire) at 12 weeks during m. Secondary endpoints were QoL over time, activity and safety of CT arms. A sample of 49 pts per arm (not progressed during initial CT and during m therapy for at least 12 weeks) will have 91% chance to have 12-point Minimal Interesting Difference (MID) between arms for EQ5D-VAS, and 87% chance to find 0.137 MID between arms for EQ5D-I. It is assumed that about 20% of pts in both arms experienced a PD before to evaluate primary endpoint. The study sample was then increased to 118. Results: From 1/2011 to 3/2012, 118 pts were randomized to CP (n=60) or CbTBe (n=58). Baseline demographics were well balanced across arms; overall 74% male, 79% PS 0 and 94% stage IV. Treatment differences (mean change from baseline), EQ5D-VAS = 1.82 (95%CI -8.60 to 12.24; P=0.73), EQ5D-I = 0.15 (95%CI 0.01 to 0.29), favoured arm A. Conclusions: CP-mP showed better (over the MID) health profile (EQ5D-I) at 12 weeks as compared to CbBe-mBe. EQ5D-VAS didn’t find any significant difference between treatment arms. Clinical trial information: NCT01303926.
33
Colucci, G., R. Labianca, F. Di Costanzo, V. Gebbia, G. Cartenì, B. Massidda, L. Frontini, M. Falconi, C. Gallo, and M. Di Maio. "A randomized trial of gemcitabine (G) versus G plus cisplatin in chemotherapy-naive advanced pancreatic adenocarcinoma: The GIP-1 (Gruppo Italiano Pancreas— GOIM/GISCAD/GOIRC) study." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): 4504. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.4504.
Full textAbstract:
4504 Background: Single-agent gemcitabine (G) remains standard treatment for advanced pancreatic adenocarcinoma (APC). The GIP-1 randomized phase III trial (clinicaltrials.gov ID NCT00813696 ) was performed to compare the combination of cisplatin (P) and G vs. G alone as 1st-line treatment. Methods: Patients (pts) with locally advanced and/or metastatic pancreatic adenocarcinoma, age 18–75, Karnofsky Performance Status (KPS) ≥50, were randomized to receive G (arm A) or G+P (arm B). In arm A, G was administered at 1000 mg/m2 weekly for 7 consecutive wks, and, after a 2-week rest, on day 1, 8, 15 every 4 wks. In Arm B, P 25 mg/m2 weekly (with the exception of day 22) was added to G, same dose used in Arm A (Colucci et al, Cancer 2002; 94:902–10). No maximum number of cycles was planned. Primary endpoint was overall survival (OS). Clinical benefit (CB), objective response rate (ORR), progression-free survival (PFS), toxicity and quality of life were secondary endpoints. To have 80% power of detecting a 0.74 Hazard Ratio (HR) of death (corresponding to increase in median OS from 4.8 to 6.5 months, with bilateral alpha=0.05, 400 pts were planned and 355 deaths were required for final analysis. Results: From April 2002 to April 2007, 400 pts were enrolled (A:199, B; 201) in 46 Italian Institutions. Median age was 63 yrs (range 35–75), 59% were males, 84% stage IV, 83% KPS≥80. After a median follow-up of 38.2 months and 357 deaths, median OS was 8.3 vs 7.2 months in arm A and B, respectively (HR 1.10, 95% CI 0.89–1.35, p=0.38). Median PFS was 3.9 vs 3.8 months in arm A and B, respectively (HR 0.97, 95% CI 0.80–1.19, p=0.80). ORR was 10.1% in arm A and 12.9% in B (p=0.37). CB response was experienced by 23.0% and 15.1% (Arm A vs B, p=0.057). Patients assigned to combination arm experienced more anaemia (all grades: 50% vs 39%, G3: 5% vs 1%), more neutropenia (all grades: 44% vs 36%, G3&4: 25% vs 14%) and more thrombocytopenia (all grades: 57% vs 29%, G3&4: 16% vs 5%). No relevant differences were seen in non-haematological toxicity. Conclusions: Weekly combination of P and G, compared to single-agent G as 1st-line treatment of APC, failed to demonstrate any improvement in OS, PFS, ORR and clinical benefit. No significant financial relationships to disclose.
34
Conti, Sergio. "Didattica delle lingue a distanza durante l’emergenza Covid-19: il quadro generale." Ripensare l’insegnamento delle lingue straniere a partire dall’esperienza della didattica a distanza 8, no. 2 (November 30, 2021): 9–52. http://dx.doi.org/10.21283/2376905x.14.245.
Full textAbstract:
IT In seguito allo spostamento delle attività didattiche online al fine di contenere la diffusione della malattia da nuovo Coronavirus, il Gruppo di Ricerca e azione sull’Apprendimento delle Lingue ha diffuso un questionario volto a valutare l’impatto della didattica a distanza sull’insegnamento delle lingue straniere durante. All’indagine hanno partecipato 136 docenti e 241 studenti, sia universitari che di scuola secondaria. Scopo del presente contributo è quello di descrivere la composizione del questionario e del campione dei rispondenti, e di riportare i principali risultati. In particolare, dall’indagine sono emersi: (i) una mancanza di chiare direttive da parte delle istituzioni scolastiche, sintomo del carattere emergenziale delle misure intraprese; (ii) una generale resistenza a sperimentare formati didattici inediti e più adeguati al mezzo digitale; (iii) il maggiore svantaggio nello sviluppo delle abilità interazionali e di produzione orale; (iv) un alto grado di criticità nel garantire l’affidabilità e l’integrità delle prove di valutazione. Parole chiave: DIDATTICA A DISTANZA; COVID-19; DIDATTICA DELLE LINGUE STRANIERE EN The shift to online teaching aimed at containing the spread of Coronavirus has led the group of Research and Action on Foreign Language Teaching to release a survey with the purpose of assessing the impact of remote instruction on foreign language teaching. 136 teachers and 241 students at both the university and secondary level have participated in this survey. The aim of this article is to describe the content of the survey and the make-up of the participants and to present the main findings. Of particular note from this survey is (i) the lack of clear directives from their educational institutions, which is a symptom of the immediate nature of the measures put into place; (ii) a generalized resistance to experiment with new pedagogical resources that are better suited for the digital format; (iii) the greatest challenge in developing the ability to interact and to communicate orally; (iv) a high level of difficulty in guaranteeing the trustworthiness and the integrity of the assessments. Key words: REMOTE TEACHING; COVID-19; FOREIGN LANGUAGE TEACHING ES El cambio a la enseñanza en línea que se ha producido para contener la propagación del Coronavirus ha llevado al Grupo de Investigación y Acción sobre la Enseñanza de Lenguas Extranjeras a publicar una encuesta con el objetivo de evaluar el impacto de la instrucción a distancia en la enseñanza de lenguas extranjeras. En dicha encuesta participaron 136 profesores y 241 estudiantes de nivel universitario y secundario. El objetivo de este artículo es describir el contenido de la encuesta y la composición de la muestra, así como presentar los principales hallazgos. De esta encuesta cabe destacar (i) la falta de directrices claras por parte de las instituciones educativas, lo que es un síntoma del carácter contingente de las medidas implementadas; (ii) una resistencia generalizada a experimentar con nuevos recursos pedagógicos mejor adaptados al formato digital; (iii) una gran desventaja en el desarrollo de la capacidad de interacción y comunicación orales; (iv) un alto nivel de dificultad para garantizar la fiabilidad y la integridad de las evaluaciones. Palabras clave: ENSEÑANZA A DISTANCIA; COVID-19; ENSEÑANZA DE LENGUAS EXTRANJERAS
35
Colucci, Giuseppe, Roberto Labianca, Francesco Di Costanzo, Vittorio Gebbia, Giacomo Cartenì, Bruno Massidda, Elisa Dapretto, et al. "Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study." Journal of Clinical Oncology 28, no. 10 (April 1, 2010): 1645–51. http://dx.doi.org/10.1200/jco.2009.25.4433.
Full textAbstract:
PurposeSingle-agent gemcitabine became standard first-line treatment for advanced pancreatic cancer after demonstration of superiority compared with fluorouracil. The Gruppo Italiano Pancreas 1 randomized phase III trial aimed to compare gemcitabine plus cisplatin versus gemcitabine alone (ClinicalTrials.gov ID NCT00813696).Patients and MethodsPatients with locally advanced or metastatic pancreatic cancer, age 18 to 75 years, and Karnofsky performance status (KPS) ≥ 50, were randomly assigned to receive gemcitabine (arm A) or gemcitabine plus cisplatin (arm B). Arm A: gemcitabine 1,000 mg/m2weekly for 7 weeks, and, after a 1-week rest, on days 1, 8, and 15 every 4 weeks. Arm B: cisplatin 25 mg/m2added weekly to gemcitabine, except cycle 1 day 22. Primary end point was overall survival. To have 8% power of detecting a 0.74 hazard ratio (HR) of death, with bilateral α .05, 355 events were needed and 400 patients planned.ResultsFour hundred patients were enrolled (arm A: 199; arm B: 201). Median age was 63, 59% were male, 84% had stage IV, and 83% had KPS ≥ 80. Median overall survival was 8.3 months versus 7.2 months in arm A and B, respectively (HR, 1.10; 95% CI, 0.89 to 1.35; P = .38). Median progression-free survival was 3.9 months versus 3.8 months in arm A and B, respectively (HR, 0.97; 95% CI, 0.80 to 1.19; P = .80). The objective response rate was 10.1% in A and 12.9% in B (P = .37). Clinical benefit was experienced by 23.0% in A and 15.1% in B (P = .057). Combination therapy produced more hematologic toxicity, without relevant differences in nonhematologic toxicity.ConclusionThe addition of weekly cisplatin to gemcitabine failed to demonstrate any improvement as first-line treatment of advanced pancreatic cancer.
36
Bengala, C., C. Zamagni, P. Pedrazzoli, P. Matteucci, A. Ballestrero, G. Da Prada, M. Martino, et al. "Cardiac tolerability of trastuzumab in metastatic breast cancer (MBC) patients previously treated with high-dose chemotherapy (HDC) with autologous hemopoietic support: Retrospective analysis from Gruppo Italiano Trapianto Midollo Osseo (GITMO) Solid Tumor Working Party." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 10558. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.10558.
Full textAbstract:
10558 Background: HER-2 overexpression is associated to a poor prognosis in high-risk and MBC patients treated with HDC. HER-2 status is also a predictive factor of response to trastuzumab: when trastuzumab is administered in combination with or sequentially to chemotherapy, a significant DFS and/or survival improvement has been observed in HER2+ early and MBC. Unfortunately, in both settings, trastuzumab was associated with an increased risk of cardiac dysfunctions (CD). Patients and Methods: In order to evaluate the cardiac safety of trastuzumab after HDC, we have reviewed the clinical charts of HER2-overexpressing MBC patients treated with HDC and trastuzumab at 11 centres of the GITMO group. Age, baseline LVEF, radiation therapy on cardiac area, exposure to anthracycline, single or multiple transplant, high-dose agents, trastuzumab treatment duration were recorded as potential risk factors. Cardiac dysfunction (CD) was defined as: 1) decline of LVEF ≥ 10% to below 50%, 2) decline of LVEF between 5 and 9% to below 50% with symptomatic (NYHA class III-IV) congestive heart failure (CHF), 3) any symptomatic CHF event. Results: Fifty-three patients treated between 1999 and 2005 have been included in the analysis. Median age was 47 years (range 29–66). Median interval between HDC and trastuzumab was 6 months. Median LVEF at baseline was 60.5%; at the end of trastuzumab (data available for 28 patients only) it was 55% (p = 0.01). Five out of the 28 (17.9%) pts experienced CD. Two out of 53 (3.8%) pts developed a symptomatic (NYHA class III) CHF. Age ≥ 50 years was the only factor significantly associated with CD. However age ≥ 50 years and multiple transplant procedure were associated with a significant decline of LVEF (p: 0.02). Conclusion: The incidence of CD is not superior to that reported with trastuzumab after standard chemotherapy. However pts with age ≥ 50 years or receiving multiple course of HDC, should be considered at risk for CD. No significant financial relationships to disclose.
37
Szram, Mariusz. "Origene e l’allesandrinismo capadoce (III-IV secolo). Atti del V Convegno del Gruppo Italiano di ricerca su „Origene e la tradizione alessandrina" (Bari, 20-22 settembre 2000), a cura di M. Girardi - M. Morin, Bari 2002, Quaderni di „Vetera Christianorum"." Vox Patrum 44 (March 30, 2003): 461–66. http://dx.doi.org/10.31743/vp.8102.
Full text
38
Feltz, Adalbert. "Untersuchungen über Halogenverbindungen der IV. Gruppe; Äthylammonium-tetrachlorooxotitanat." Zeitschrift für Chemie 7, no. 4 (September 2, 2010): 158. http://dx.doi.org/10.1002/zfch.19670070418.
Full text
39
Goldaniga, Maria, Francesco Merli, Caterina Stelitano, Vincenzo Callea, Fiorella Ilariucci, Mario Russo, Patrizio Mazza, et al. "Front-Line Treatment of Low-Grade Non-Follicular Non-Hodgkin Lymphoma (Final Report of Gisl LL02 Trial)." Blood 110, no. 11 (November 16, 2007): 2332. http://dx.doi.org/10.1182/blood.v110.11.2332.2332.
Full textAbstract:
Abstract Indolent Non-follicular non-Hodgkin Lymphoma (NFo-NHL) is a group of relatively frequent lymphoproliferative diseases, nevertheless extended clinical and prognostic studies are still lacking. In 2002 the Gruppo Italiano Studio Linfomi (GISL) initiated a LL02 prospective multicenter phase II trial, with the aim to evaluate the efficacy and safety of FC combination in the first-line therapy of NFo-NHL patients younger than 70 years. Between July 2002 and September 2006, 58 adult patients (35 males and 23 females, median age 64 yrs, range 40–75) affected by NFo-NHL in active disease phase, were consecutively enrolled in 12 GISL Hematological Centres. Patients were treated with a dose of 25 mg/mq Fludarabine plus 250 mg/mq Cyclophosphamide administred intravenously daily for 3 days; each cycle was repeated every 28 days for 6 courses. During the treatment patients received oral thrimethoprim-sulphametoxazole prophylaxis. After the intermediate evaluation, 48/58 patients (82.8%) had an objective response (ORR) with a 20.7% of complete remission (CR) plus 62.1% of partial remission (PR); at the final evaluation the ORR percentage was 84.5% with a 41.4% of CR (24 pts) and 43.1% of PR (25 pts); three patients were in progressive disease (5.2%) and one in stable disease (1.7%). The median overall survival (OS) was not reached with an 88% and 84% at 12 and 24 months; the progression free survival (PFS) was 89% and 77% and the event free survival (EFS) was 81% and 66% at 12 and 24 months respectively.About the toxicity profile, the major toxicity was hematological with a 18% cases of WHO grade III or IV anemia, 40% leucopenia, 33% neutropenia and 10% piastrinopenia. The 12% of patients had an infective episode wich a 7.7% of WHO grade III–IV.In conclusion the FC chemotherapy is a useful chance for advanced untreated non follicular low-grade NHL, with an optimal ORR, CR and PFS. The crucial point of FC remains OS, that not seems to be significantly improved in comparison with fludarabine alone or with standard therapy, even though the better quality of responses; Rituximab plus FC association is growing in literature as the probably key to find a real improvement also in this aspect.
40
Tirelli, Umberto, Lucia Fratino, Monica Balzarotti, Lilj Uziel, Annalisa Giacalone, Andres Ferreri, Armando Santoro, and Michele Spina. "Comprehensive Geriatric Assessment-Adapted Chemotherapy in Elderly Patients (>70 years) with Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL): Final Results and Long Term Follow-up." Blood 114, no. 22 (November 20, 2009): 2684. http://dx.doi.org/10.1182/blood.v114.22.2684.2684.
Full textAbstract:
Abstract Abstract 2684 Poster Board II-660 Background: R-CHOP is the standard treatment for elderly patients (pts) with DLBCL. Many pts aged 70 years (yrs) or more are unable to receive R-CHOP and the majority of them are excluded from clinical trials. Comprehensive geriatric assessment (CGA) is an useful instrument to predict the clinical outcome of elderly pts with cancer. Within the GOL (Gruppo Oncoematologico Linfomi) we started a phase II study aiming to evaluate feasibility and activity of a CGA-driven chemotherapy for elderly pts with DLBCL Material and methods: Pts with no comorbidity received CHOP/R-CHOP; pts with mild cardiopathy received epirubicin instead of doxorubicin; in pts with moderate/severe cardiopathy the use of anthracyclines was omitted; pts with diabetes did not receive prednisone; in pts with neuropathy vincristine was omitted. The dosage of chemotherapy was decided according to CGA: pts with a good score (ADL=6 and IADL>6) received full doses of CT; pts with an intermediate score (ADL=5 and IADL>4) received 75% of the dose; pts with a poor score (ADL<5 and IADL<5) received 50% of the dose. Results: One hundred pts (41 males and 59 females) have been treated. The median age was 75 yrs and stages III-IV were diagnosed in 51% of pts. 61% of pts received full doses of CT; 25% received 75% of dose and 14% received 50% reduced dose; 86% of pts received an anthracycline and 54% rituximab. Toxicity was quite acceptable. Grade 3–4 neutropenia was observed in 30% of pts, mucositis in 12%, and peripheral neuropathy in 9%. Four toxic deaths were observed. Overall, 81% of pts achieved complete remission; with a median follow-up of 50 months, 20% of them have relapsed. The 5 yr-OS, DFS, EFS are 58%, 78% and 50%. It is remarkable that the 5-year specific survival is 72%. Conclusions: Our results demonstrate that a CGA-driven approach is feasible in elderly pts with DLBCL. This strategy allows to offer a curative approach to all pts with aggressive NHL, avoiding to under treat pts with a potentially cured disease or over treat pts with severe comorbidities. Disclosures: No relevant conflicts of interest to declare.
41
Gebbia, V. "Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB–IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale." Lung Cancer 39, no. 2 (February 2003): 179–89. http://dx.doi.org/10.1016/s0169-5002(02)00444-0.
Full text
42
Silingardi, Mauro, Stefano Luminari, Elisa Barbolini, Fiorella Ilariucci, Dimitriy Arioli, Nicola Di Renzo, Carlo Visco, et al. "Incidence Rate of Thromboembolic Events (TE) In a Prospectively Evaluated Population of Patients with Lymphoma Enrolled In First Line Treatment Clinical Trials: a Report From the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL)." Blood 116, no. 21 (November 19, 2010): 4208. http://dx.doi.org/10.1182/blood.v116.21.4208.4208.
Full textAbstract:
Abstract Abstract 4208 Introduction: Patients with lymphoma are considered at high risk of thrombosis, due to the disease itself or to the use of chemotherapy. The global risk of thrombosis is around 5%, higher in Non Hodgkin Lymphoma compared to Hodgkin Lymphoma and in advanced stages compared to localized disease. So far few studies have addressed the risk of thrombosis in lymphomas with a prospective approach. In 2007 we started a prospective study on patients with malignant lymphoma (ML) to assess the risk of thromboembolism in such patients and to identify possible risk factors. Methods: from March 1st 2007 all patients enrolled in any of the active clinical trials conducted by the Gruppo Italiano Studio Linfomi for the initial treatment of ML were screened for the occurrence of thromboembolic events (TE) at 3 timepoints: at the time of diagnosis (D), during chemotherapy (C) and during follow-up (F). For each registered TE additional data were required with respect to presence of additional risk factors (drugs, bed stay, comorbidities), concomitant use of anticoagulants, venous catheter implant. A detailed description of TE with treatment and outcome details was also required. Results: as of July 20th 2010, 643 patients have been registered in an active GISL clinical trial. Lymphoma subtype was Follicular Lymphoma (FL) in 70%, Indolent Non Follicular Lymphoma (INFL) in 10%, Hodgkin Lymphoma (HL) in 6%, Mantle Cell Lymphoma (MCL) in 6%, Diffuse Large B Cell Lymphoma (DLBCL) in 7%. Patients had a median age of 57 years (range 16 to 86), the male to female ratio was 1.16: Stage was advanced (III-IV) in 84%. Median follow-up was 18 months. Overall 27 TE have been reported, which corresponds to a proportion of 4.4%. Most events occurred during treatment or follow-up (15 and 6 at C and F timepoints, respectively), while TE proportion at D was low (0.9%). TE rate (×100 person-year) was 3.9 in MCL, followed by other lymphoma subtypes: HL 3.8, FL 2.6, DLBCL 2.4, and INFL 1.8. Interestingly, in MCL all the TE occurred at the C and F timepoints, and these patients were treated with an intense chemotherapy regimen (alternating R-hyperCVAD and HD ARA-C and mtx), while other lymphomas received conventional dose chemotherapy. Overall, the only parameter associated with TE development was PS>2 (RR 6.2, P=0.013), while the RR is 3.8 (P=0.188) if the 21 TE at C+F timepoints are considered. So far, detailed informations concerning TE were received for 20 patients. Of these, only 3 had comorbidities (1 case of diabetes mellitus, 1 case of cardiovascular disease and 1 case of prostatic adenocarcinoma receiving hormonotherapy) and no prior DVT or PE have been described. Two of the 5 cases of bedridden patients stayed in bed for more than 7 days before experiencing TE. Seventeen patients took no thrombogenic drugs as ongoing estroprogestinic therapy or hormonotherapy. Five patients had a venous catheter implant, which was removed only in 1 case due to thromboembolic occurrence. Overall we registered 7 cases of PE and 13 cases of DVT. When looking at the TE event description, 14 patients have been recorded as symptomatic and 4 were already treated with anticoagulants when the TE was diagnosed. The most frequent sites of TE were femoral vein or jugular vein (3 and 3 events, respectively), while the principal diagnostic tool employed for the TE diagnosis was Color Doppler ultrasound. Conclusions: To the best of our knowledge this is the study with the highest number of newly diagnosed patients with ML prospectively considered for the risk of TE. It shows a lower than expected rate of TE, probably because there is a representation of the different histotypes which doesn't replicate the real incidence: Follicular Lymphoma, a subtype with low risk of TE, is certainly over-represented. Our data suggest that therapy is the most important cause for TE. Further analyses on reported events may help to identify additional risk factors. Disclosures: No relevant conflicts of interest to declare.
43
Silva, C. A., L. A. F. Silva, A. J. Mesquita, M. C. S. Fioravanti, and C. S. Acypreste. "Microbiota anaeróbia isolada de bovinos com pododermatite." Arquivo Brasileiro de Medicina Veterinária e Zootecnia 51, no. 3 (June 1999): 207–12. http://dx.doi.org/10.1590/s0102-09351999000300001.
Full textAbstract:
O presente trabalho teve como objetivo isolar e identificar espécies bacterianas anaeróbias presentes nos pés de bovinos portadores de vários graus de pododermatite. Foram utilizados 60 bovinos, distribuídos em quatro grupos de 15. O grupo I foi constituído por animais saudáveis e serviu de controle; o grupo II, por bovinos na fase inicial do processo; o grupo III, por animais portadores de pododermatite interdigital vegetativa e o grupo IV, por bovinos portadores de pododermatite necrosante. Foram colhidos fragmentos de tecido interdigital para cultura e as principais espécies bacterianas isoladas foram: Dichelobacter nodosus nos grupos II, III e IV e Fusobacterium necrophorum nos grupos III e IV, com freqüências de 26,7%, 6,7%, 20,0%, 6,7% e de 13,3%, respectivamente. Encontraram-se também Fusobacterium symbiosum em 40,0% no gb>rupo I, 6,7% no grupo II, 13,3% no grupo III e 13,3% no grupo IV, Bacteroides sp. em 6,7% nos grupos I e IV, Bacteroides ruminatus em 33,3% no grupo I, 6,7% no grupo II, 33,3% no grupo III e 13,3% no grupo IV, Bacteroides oralis em 6,7% no grupo III e Fusobacterium mortiferum em 6,7% no grupo IV.
44
Ciudad Ruiz, Andrés, and Carlos M. Varela Scherrer. "Fiesta y ritual en el Grupo IV de Palenque." Estudios de Cultura Maya 58 (June 27, 2021): 11–44. http://dx.doi.org/10.19130/iifl.ecm.2021.58.23861.
Full textAbstract:
The collective ceremonies, whether of a community or family nature, were hierarchical in the societies of the Mayan Lowlands of the Classic period, and were designed within the framework of a wide range of purposes; so its footprint in the archaeological record also presents a high degree of variation. Many of these rituals culminated in the celebration of festivals and meals that, on rare occasions, reveal a similar "archaeological physiognomy" and make it difficult to interpret their nature. In this essay we analyze a ritual deposit excavated behind the J3 Structure of Group IV of Palenque, an elite residential space occupied by one of the most distinguished noble lineages of the city, as well as the collective ingestion of foods and beverages by its officiants and assistants.
45
Feltz, A., and H. Grohmann. "Untersuchungen über Halogenverbindungen der IV. Gruppe; Ti2OBr6 · 4CH3CN, ein durch Solvatation stabilisiertes Titan(IV)-oxidbromid." Zeitschrift für Chemie 6, no. 10 (September 2, 2010): 388. http://dx.doi.org/10.1002/zfch.19660061019.
Full text
46
Miranda-Medina, Adriana, Jorge A. Gutiérrez-Espinosa, Ma Teresa Colinas-León, Lourdes Arévalo-Galarza, and E. Araceli Gaytán-Acuña. "PRODUCCIÓN INVERNAL DE PERRITO DE CORTE (Antirrhinum majus L.) EN EL VALLE DE MÉXICO." Revista Fitotecnia Mexicana 31, no. 3 (September 30, 2008): 251. http://dx.doi.org/10.35196/rfm.2008.3.251.
Full textAbstract:
El desarrollo y calidad comercial de cuatro cultivares de perrito (Antirrhinum majus L.) del Grupo I (‘Flamingo’, ‘Yosemite Pink’, ‘White-Ivory’ y ‘EuroRose’) y dos del Grupo IV (‘Rose’ y ‘White’) se evaluaron en un invernadero de cristal durante el ciclo de invierno 2004 en Montecillo, México. Los cultivares Grupo IV, produjeron tallos con 24 % más de peso y 8 % más de longitud que los del Grupo I, por lo que el Grupo IV logró mayor índice de calidad comercial (0.68 g cm-1) que el Grupo I (0.53 g cm-1). La calidad comercial “Especial”, considerada la más alta por la Sociedad Americana de Floristas, se obtuvo en todos los tallos del Grupo IV, mientras que sólo 66.5 % de los tallos producidos por el Grupo I lograron esta clasificación. Es factible la producción de invierno con calidad comercial “Especial” de los cultivares del Grupo IV en invernaderos sin calefacción del valle de México, aunque requieren 25 d más para alcanzar la madurez comercial que los cultivares del Grupo I.
47
Alievi, M. M., A. N. C. Oliveira, P. A. Ferreira, C. Traesel, L. D. Guimarães, F. Flores, S. F. Silva, and J. E. W. Schossler. "Osteossíntese de úmero em pombos domésticos (Columba livia) associando-se pinos metálicos e polimetilmetacrilato intramedulares após osteotomia diafisária." Arquivo Brasileiro de Medicina Veterinária e Zootecnia 60, no. 4 (August 2008): 843–50. http://dx.doi.org/10.1590/s0102-09352008000400011.
Full textAbstract:
Foram utilizadas 28 aves adultas, separadas aleatoriamente em quatro grupos. Os pombos foram anestesiados com isoflurano para a realização da osteotomia diafisária transversa do úmero direito. No grupo I, a osteossíntese foi realizada associando-se dois pinos de Kirschner e polimetilmetacrilato, intramedulares; no grupo II, os pinos de Kirschner foram substituídos por pinos de Schanz; no grupo III, foram utilizados apenas dois pinos de Kirschner; e, no grupo IV, apenas dois pinos de Shanz. Os tempos médios para a consolidação óssea foram de 29±4,04 dias no grupo I; 24±5,29 dias no grupo II; 33±3,74 dias no grupo III; e 32,9±5,21 dias no grupo IV. Foi observada migração dos pinos em 42,9% dos animais do grupo I, em 0% nos do grupo II, em 85,7% nos do grupo III, e em 28,6% nos do grupo IV. Em duas aves dos grupos I, III e IV notou-se incapacidade de voar. Os resultados demonstram que a associação de dois pinos de Schanz e polimetilmetacrilato, ambos intramedulares, é um método efetivo para osteossíntese de úmero em pombos domésticos (Columba livia), proporcionando rápida consolidação óssea e mínimas complicações.
48
Pancerz, Roland Marcin. "Hermeneutyka antropomorfizmów biblijnych u Dydyma Ślepego." Vox Patrum 55 (July 15, 2010): 521–34. http://dx.doi.org/10.31743/vp.4354.
Full textAbstract:
Uno dei scrittori del IV secolo, che si è inserito nella controversia antropomorfita sorta in quel secolo tra i monaci del deserto egiziano, è Didimo il Cieco d’Alessandria. Nel suo Commento ai Salmi troviamo due immediate menzioni del gruppo degli antropomorfiti e la confutazione del loro errore. L’Alessandrino rimprovera loro di riferire l’essere ad immagine di Dio (Gen 1, 26) al corpo umano, di capire gli antropomorfismi biblici su Dio letteralmente, e in conseguenza di credere che Dio veramente abbia membra umane e una forma esteriore. Commentando molti frammenti biblici che parlano di Dio in questo modo, Didimo spesso mette in rilievo la necessità di un’adeguata interpretazione di tali espressioni. Il fondamentale principio interpretativo – desunto peraltro dalla tradizione anteriore – è quello di intendere queste parole qeoprepîj, cioè in modo degno di Dio, adeguato alla natura di Dio. Il significato degli antropomorfismi non può essere quello suggerito immediatamente dalla lettera della Scrittura, ma deve essere strettamente sottoposto al concetto della realtà a cui essi si riferiscono. Si deve quindi tener conto che Dio è un essere immateriale, spirituale, invisibile, privo di forma e grandezza, incomposto, immutabile, non legato ad alcun posto e libero dalle passioni umane. Nella sua teoria ermeneutica Didimo sembra pure richiamare l’attenzione sulla regola dell’analogia della fede. Nell’interpretazione degli antropomorfismi trova un ampio uso il metodo allegorico, ciò che del resto è tipico per la scuola alessandrina. Così lo scrittore ricava dalle espressioni antropomorfiche della Scrittura diversi significati, non di rado molto profondi: „il volto” di Dio è per esempio il Figlio di Dio oppure la stessa esistenza di Dio, le sue idee o la sua salvezza; lo scrutare gli uomini attraverso „le palpebre” (Sal 10, 4) esprime la divina clemenza nel giudizio; „il grembo” e „il cuore” di Dio Padre, da cui è generato il Figlio, indicano la stessa sostanza del Padre; “le mani” di Dio significano le sue varie potenze (creatrice, punitiva, protettrice), poi i due Testamenti, e infine il Figlio e lo Spirito Santo – due mediatori del Padre nella creazione del mondo; “l’ira” di Dio indica un castigo o un travaglio mandati da Lui, oppure le potenze che fanno il servizio di punizione. Ovviamente in queste interpretazioni Didimo risente spesso della tradizione anteriore (Filone e Origene). Grazie alla presa di posizione contro l’antropomorfismo Didimo appare a noi come un teologo maturo che difende l’immaterialità e la trascendenza di Dio, sa interpretare saggiamente la Scrittura e riesce a ricavarne numerosi e validi contenuti teologici.
49
Cauletti, Carla, and Claudio Furlani. "Struttura elettronica e legame chimico in composti organometallici di stagno (IV) e piombo (IV) con gruppi insaturi." Rendiconti Lincei 2, no. 3 (September 1991): 191–200. http://dx.doi.org/10.1007/bf03002946.
Full text
50
Gómez Hinojosa, Antonia Maria. "Resultados de un Tratamiento Grupal en pacientes diagnosticados de Esquizofrenia Paranoide sobre la Calidad de Vida y el Estado Sintomático." Revista de Psicoterapia 25, no. 99 (November 1, 2014): 165–82. http://dx.doi.org/10.33898/rdp.v25i99.19.
Full textAbstract:
Introducción: Pero la actual ampliación de dichos objetivos terapéuticos en el tratamiento de la esquizofrenia añade la evaluación de la calidad de vida como indicador de resultados en la actuación terapéutica. El objetivo de este estudio fue evaluar el efecto de una intervención psicosocial grupal sobre la calidad de vida subjetiva, el estado sintomático y el número y duración de las recaídas en personas diagnosticadas de esquizofrenia paranoide.Metodología: Se seleccionaron 30 pacientes con esquizofrenia paranoide (criterios DSM-IV) de un centro de salud mental del maresme. De estos, se seleccionaron al azar 15 participantes que se asignaron al grupo tratamiento y 15 al grupo control. Se administraron dos instrumentos de evaluación: el Cuestionario Sevilla de Calidad de Vida (CSCV) (Giner et al., 1995) y la Escala de Síntomas Positivo y Negativo (PANSS) (Peralta y Cuesta, 1994), antes del inicio del tratamiento grupal, a los 12 meses y a los 24 meses del inicio del mismo.Resultados: El grupo tratamiento mejoró significativamente en la calidad de vida, el estado sintomático y en el número y duración de las recaídas al cabo de los 12 meses del inicio de la intervención. Dicha mejora se mantuvo al cabo de los 24 meses del inicio del tratamiento. En la comparación con el grupo control la significación estadística de mejora no fue tan evidente.